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A B S T R A C T
Background
Older people with hip fractures are often malnourished at the time of fracture, and have poor food intake subsequently.
Objectives
To review the effects of nutritional interventions in older people recovering from hip fracture.
Search strategy
We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (September 2008), the Cochrane Central
Register of Controlled Trials (The Cochrane Library 2008, Issue 3), MEDLINE and other major databases (to July 2008).
Selection criteria
Randomised and quasi-randomised controlled trials of nutritional interventions for people aged over 65 years with hip fracture.
Data collection and analysis
Both authors independently selected trials, extracted data and assessed trial quality. We pooled data for primary outcomes.
Main results
Twenty-four randomised trials involving 1940 participants were included. Outcome data were limited and many trials were method-
ologically flawed. Results from 23 trials are presented here.
Ten trials evaluated oral multinutrient feeds: providing non-protein energy, protein, some vitamins and minerals. Oral feeds had no
statistically significant effect on mortality (16/244 versus 21/226; risk ratio (RR) 0.76, 95% confidence interval (CI) 0.42 to 1.37) or
’unfavourable outcome’ (combined outcome of mortality and survivors with medical complications) (46/126 versus 41/103; RR 0.76,
95% CI 0.55 to 1.04).
Four heterogenous trials examining nasogastric multinutrient feeding showed no evidence of an effect on mortality (RR 0.99, 95% CI
0.50 to 1.97). Nasogastric feeding was poorly tolerated.
One trial examining nasogastric tube feeding followed by oral feeds found no evidence for an effect on mortality or complications.
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One trial of multinutrient intravenous feeding followed by oral supplements found a reduction in participants with complications (RR
0.21, 95% CI 0.10 to 0.46), but not in mortality (RR 0.11, 95% CI 0.01 to 2.00).
Four trials testing increasing protein intake in an oral feed found no evidence for an effect on mortality (RR 1.42, 95% CI 0.85 to
2.37). Protein supplementation may have reduced the number of long term medical complications.
Two trials, testing intravenous vitamin B1 and other water soluble vitamins, or oral 1-alpha-hydroxycholecalciferol (vitamin D)
respectively, produced no evidence of effect.
One trial, evaluating dietetic assistants to help with feeding, showed no statistically significant effect on mortality (RR 0.57, 99% CI
0.29 to 1.11).
Authors’ conclusions
Weak evidence exists for the effectiveness of protein and energy feeds. Adequately sized randomised trials with robust methodology are
required. In particular, the role of dietetic assistants, and peripheral venous feeding require further evaluation.
P L A I N L A N G U A G E S U M M A R Y
Nutritional supplementation for older people after hip fracture
Older people with hip fractures are often malnourished at the time of their fracture and many have poor food intake while in hospital.
Malnutrition may hinder recovery after hip fracture. We reviewed the effects of nutritional interventions in older people recovering
from hip fracture.
The 24 randomised controlled trials included in this review involved 1940 participants. The trials had methodological flaws that may
affect the validity of their results. Ten trials examined the use of additional feeds by mouth providing non-protein energy, protein, some
vitamins and minerals. Pooled data from these trials found that there may be a possibility of a reduction in ’unfavourable outcome’
(combined outcome of mortality and survivors with medical complications), but no effect on mortality.
Four trials examined nasogastric tube feeding, where liquid food is delivered via a tube inserted into the nose and passed down into
the stomach, with non-protein energy, protein, some vitamins and minerals. These trials provided very limited data but tube feeding,
which was poorly tolerated, did not seem to make a difference to mortality.
One trial found nasogastric tube feeding followed by oral feeds did not seem to affect mortality or complications.
One trial examined giving feed into a vein initially, then bymouth. This did not seem to affectmortality but might reduce complications.
Increasing protein intake in an oral feed was tested in four trials. Protein supplementation may have reduced the number of long term
complications, but it did not seem to make a difference to mortality alone.
Two trials examining intravenous vitamin B1 and other water soluble vitamins, or a form of vitamin D given orally, did not alter
outcomes.
One unpublished study comparing ornithine alpha-ketoglutarate with an isonitrogenous peptide supplement found very weak evidence
of a delay in the onset of complications but not their occurrence.
One trial, evaluating dietetic assistants to help improve nutritional intake found a trend for a reduction in mortality.
Some evidence exists for the effectiveness of protein and energy feeds, but overall the evidence for the effectiveness of nutritional
supplementation remains weak. The role of dietetic assistants, and peripheral intravenous feeding require further evaluation. Trials are
required which overcome the defects of the reviewed studies, particularly inadequate size and trial methods.
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B A C K G R O U N D
Description of the condition
Fractures of the proximal femur (hip) are a cause of substantial
morbidity and mortality in older people. Nine months after their
hip fracture people still have poorer quality of life than age and
sex matched controls (Cranney 2005). In industrialised societies,
mortality in the year after hip fracture ranges from 12% to 37%,
and averages 11% during the first fewmonths after fracture (Lyons
1997). Mortality in the first four months after hip fracture surgery
is age dependent: for instance, mortality was reported as 5% in
people aged 50 to 69 years compared with 28% in those people
aged 90 years or over in the Scottish Hip Fracture Audit Report (
Holt 2008). Many people fail to return to their own homes and
previous state of mobility after a hip fracture. Acute hospital costs
are substantial, but long term costs in rehabilitation and extra care
in the community are even greater (Dolan 1998; Haentjens 2005;
Johnell 1997).
Under-nutrition leads to mental apathy, muscle wasting and re-
duced muscle power, and impaired cardiac function (Keys 1950).
All of these will impair mobility and increase the tendency to de-
velop postoperative medical complications (e.g. pneumonia, pres-
sure sores, deep venous thrombosis) and hinder recovery, both
in hospital and subsequently (Lennard-Jones 1992). Malnutrition
also impairs the immune response, which will enhance the risk of
postoperative infections (Lesourd 1997). Poor nutritional status is
associated with an increased risk of pressure ulcers after hip frac-
ture (Lindholm 2008).
People with hip fractures, who are more likely to be old and frail,
are oftenmalnourished at the time of the fracture (Bachrach2001a;
Bastow 1983a; Lumbers 2001). Social, psychological, physical,
economic, medical and cognitive influences may all contribute to
the risk of malnutrition. Surveys of dietary intake in people recov-
ering from hip fracture in hospital have recorded suboptimal in-
takes (Jallut 1990; Lumbers 2001; Nematy 2004; Patterson 1992;
Stableforth 1986a).
Description of the intervention
Examined in this review are nutrition interventions started within
the first month after a hip fracture that are aimed to improve
the intake of energy, protein, vitamins and minerals, alone or in
combination. Nutrition interventions can be provided by various
routes: oral (by mouth), enteral (tube feeding into the stomach or
small bowel, including percutaneous endoscopic gastrostomy) or
parenteral (intravenous and intramuscular). Also considered are
interventions that revolve round the administration of nutrition,
such as the use of dietetic assistants in hospital.
How the intervention might work
Making links between nutritional status and fracture recovery is
complicated by the fact that markers of dietary protein deple-
tion measured in blood, such as albumin, prealbumin, and trans-
ferrin are partly affected by fluid shifts and responses to injury
and infection.Nevertheless, associations have been shownbetween
low serum albumin and increased postoperative complications
and poorer survival (Foster 1990; Patterson 1992). Another factor
which has been implicated is vitamin C which is required for an
effective immune response and collagen formation. Low leuco-
cyte vitamin C levels have been associated with the development
of pressure sores in hip fracture patients (Brown 1992a; Goode
1992).
More direct markers of nutritional status are anthropometric in-
dices, such as weight in relation to height, triceps skinfold for body
fat, and mid-upper arm circumference for muscle and fat mass.
People with hip fracture have lower triceps skinfold and mid-up-
per arm circumference than healthy people in the same age cate-
gory (Mansell 1990; Nematy 2004). In a study of 744 hip fracture
patients, Bastow 1983a found that low triceps skinfold and arm
muscle circumference predicted lower calorie intake on the ward
and poorer survival after hip fracture. However, in a study of 40
hip fracture patients, Foster et al (Foster 1990) found that low
triceps skinfold did not predict survival.
Why it is important to do this review
The above shows that people with hip fracture are sometimes un-
dernourished, and that poor food intake may occur during routine
care, hindering recovery. There is therefore an argument for nutri-
tional supplementation in this group, and consequently a need to
evaluate the use of nutrition interventions in this group of people
by examining the evidence from relevant randomised controlled
trials. This is the sixth update of our Cochrane review first pub-
lished in 2000, and previously updated in 2006. The previous up-
date (Avenell 2006) continued to point to the insufficiency of the
available evidence to draw robust conclusions.
O B J E C T I V E S
This review examined the effectiveness, safety and acceptability
of nutrition interventions in the care of older people with hip
fracture.
We considered comparisons where people with hip fracture, who
were randomly allocated a nutrition intervention, including sup-
plements, were compared with those allocated to no intervention
or placebo. Where possible, effects were examined according to
pre-existing nutritional status:malnourished or notmalnourished.
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We also considered comparisons between nutrition interventions
if these were compared in a randomised controlled trial.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) of nutritional
supplements post hip fracture. Trials that used a quasi-randomisa-
tion technique (e.g. allocation by date of birth or hospital record
number) were also included. Trials that could not be analysed on
an intention-to-treat basis, and those that lacked blinding or use
of placebo treatment, were also included.
Studies of nutrition interventions that examined the secondary
prevention of osteoporotic fractures after hip fracture were not
considered in this review.
Types of participants
Older people recovering from any type of fracture of the hip were
included. It was anticipated that most participants would be over
65 years of age. If the number of younger participants was relatively
small, and provided there was adequate randomisation with unbi-
ased distribution of this age group between the intervention and
control groups, they were retained. Trials which focused specifi-
cally or mainly on younger people, people with multiple trauma
or people with pathological fractures (e.g. cancer-related fractures)
were excluded. Trials published before 1980 with undefined geri-
atric populations or with mixed populations with less than five
participants with hip fracture in each intervention group were ex-
cluded.
Studies reporting results on mixed populations of orthopaedic or
other geriatric patients were only included, either if separate data
were available from the participants with fracture of the hip, or
when contact with the authors resulted in the provision of such
data.
The participants studied may have resided in a hospital or in a
rehabilitation unit or any location after discharge from either of
these facilities.
Types of interventions
Examined in this review were nutrition interventions aimed to im-
prove the intake of energy, protein, vitamins andminerals, alone or
in combination. Nutrition interventions were provided by oral (by
mouth), enteral (tube feeding into the stomach or small bowel, in-
cluding percutaneous endoscopic gastrostomy) or parenteral (in-
travenous and intramuscular) routes. Interventions include those
evaluating the administration of nutrition, such as the use of di-
etetic assistants. The interventions examined were started within
the first month after hip fracture, and given for up to one year.
Trials evaluating intravenous fluid administration in the immedi-
ate post-operative period for hydration purposes were excluded.
Types of outcome measures
Information was sought on the following outcomes. As of the
update published in Issue 4, 2009, these were split into main
outcomes (and further categorised into primary and secondary
outcomes) and other outcomes. Additionally, the collection of
’unfavourable outcome’ was made explicit.
Main outcomes
Primary outcomes
• all cause mortality
• morbidity, postoperative complications (e.g. wound
infections, pressure sores, deep venous thromboses, respiratory
and urinary infections, cardiovascular events)
• ’unfavourable outcome’. This is defined as the number of
trial participants who died plus the number of survivors with
complications. Alternatively, where these data were unavailable, a
slightly different definition (mortality or survivors with a major
complication or two or more minor complications) originally
presented in Delmi 1990 was accepted.
Secondary outcomes
• length of hospital and rehabilitation unit stay
• postoperative functional status (cognitive functioning,
mobility and ability to perform activities of daily living)
• the level of care and extent of support required after
discharge
• patient perceived quality of life after discharge
• fracture healing
• putative side effects of treatment (e.g. diarrhoea, aspiration
pneumonia, specific intravenous line complications)
Other outcomes
• patient tolerance of/compliance with nutrition
interventions
• carer burden and stress
• economic outcomes
• changes in anthropometric indices, e.g. weight, skinfold
thickness, and mid-upper arm circumference
• new fractures
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• changes in bone mineral density, assessed by techniques
involving radiation, e.g. dual photon absorptiometry, dual
energy x-ray absorptiometry, quantitative computed tomography
• changes in nutritional indicators measured in blood, e.g.
albumin, transferrin, vitamin and mineral levels, haemoglobin
• changes in functional markers of nutritional status,
including delayed cutaneous hypersensitivity (a marker of
immune function) and grip strength
Search methods for identification of studies
Electronic searches
We searched the Cochrane Bone, Joint andMuscle Trauma Group
SpecialisedRegister (September 2008), theCochraneCentral Reg-
ister of Controlled Trials (The Cochrane Library 2008, Issue 3),
MEDLINE (1966 to July 2008), Nutrition Abstracts and Reviews
(1984 to July 2008), EMBASE (1980 to week 32 2008), BIOSIS
(1985 to 14 August 2008), CINAHL (1982 to August week 2
2008), and HEALTHSTAR (1975 to March 2002).
In MEDLINE (Ovid) the first two phases of the standard
Cochrane search strategy (Higgins 2006)were combinedwith sub-
ject-specific terms. This strategy was modified for use in other
databases (see Appendix 1 for search strategies). No language re-
strictions were applied.
We also searched Current Controlled Trials (14 August 2008),
WHO International Clinical Trials Registry Platform (6October
2009) and the National Research Register (NRR) Archive (to
September 2007) to identify ongoing trials.
Searching other resources
We handsearched Nutrition Abstracts and Reviews (publication
database) from 1960 to 1983; Clinical Nutrition: Clinical nutri-
tion: official journal of the European Society of Parenteral and
Enteral Nutrition vol 1 to vol 27 (3) 2008; American Journal of
Clinical Nutrition vol 2 to vol 88 (2) 2008; Journal of Parenteral
and Enteral Nutrition vol 1 to vol 32 (2) 2008; and Proceedings of
theNutrition Society vol 1 to vol 67(3) 2008. We also checked ref-
erence lists of articles, searched books related to orthopaedics, geri-
atric medicine and nutrition, and corresponded with colleagues
and investigators.
Data collection and analysis
Selection of studies
Both authors independently assessed reports of potentially eligible
studies. All differences were resolved by discussion.
Data extraction and management
We independently extracted data using a pre-derived data extrac-
tion form and entered the agreed results into Review Manager.
All differences were resolved through discussion. If necessary, we
contacted trialists for further information on methodology and
data.
Assessment of risk of bias in included studies
We continue to independently assess methodological quality using
a subject-specific modification of the former generic evaluation
tool developed by the Cochrane Bone, Muscle and Joint Trauma
Group. Our tool assesses aspects of internal and external validity
and scores each item between 0 and 2 (see Table 1). Additionally
we separately rated the risk of bias frompre-allocation disclosure of
assignment for presentation in the ’Risk of bias’ table, an extension
of the ’Characteristics of included studies’.
Table 1. Methodological quality assessment items
Items and scores
a. Was the assigned treatment adequately concealed prior to allocation?
2 = method did not allow disclosure of assignment (A)
1 = small but possible chance of disclosure of assignment or states random but no description(B)
0 = quasi-randomised (C)
b. Were the outcomes of participants who withdrew described and included in the analysis (intention to treat)?
2 = intention-to-treat analysis based on all cases randomised possible or carried out
1 = states number and reasons for withdrawal but intention-to-treat analysis not possible
0 = not mentioned or not possible
5Nutritional supplementation for hip fracture aftercare in older people (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Methodological quality assessment items (Continued)
c. Were the outcome assessors blinded to treatment status?
2 = action taken to blind assessors, or outcomes such that bias is unlikely
1 = small or moderate chance of unblinding of assessors
0 = not mentioned
d. Were the treatment and control group comparable at entry?
2 = good comparability of groups
1 = confounding small
0 = large potential for confounding, or not discussed
e. Were care programmes, other than the trial options, identical?
2 = care programmes clearly identical
1 = clear but unimportant differences
0 = not mentioned or clear and important differences in care programmes
f. Were the inclusion and exclusion criteria clearly defined?
2 = clearly defined
1 = inadequately defined
0 = not defined
g. Were the interventions clearly defined (including estimates of nutritional value)?
2 = clearly defined interventions are applied with a standardised protocol
1 = clearly defined interventions are applied but the application protocol is not standardised
0 = intervention and/or application protocol are poorly or not defined
h. Were the participants blind to assignment status following allocation?
2 = effective action taken to blind participants
1 = small or moderate chance of unblinding participants
0 = not possible, or not mentioned (unless double-blind), or possible but not done
i. Were the treatment providers blind to assignment status?
2 = effective action taken to blind treatment providers
1 = small or moderate chance of unblinding of treatment providers
0 = not possible, or not mentioned (unless double-blind), or possible but not done
j. Was follow-up active and appropriate?
2 = optimal
1 = adequate
0 = not defined or not adequate
k. Was the overall duration of surveillance clinically appropriate?
2 = optimal (six months or more)
1 = adequate (one up to six months)
0 = not defined, or not adequate
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Measures of treatment effect
For each study, risk ratios and 99% confidence intervals were cal-
culated for dichotomous outcomes andmean differences and 99%
confidence intervals for continuous outcomes. The choice of 99%
confidence intervals reflects the extra burden of proof we consid-
ered appropriate for individual trials, in view of their generally
poor quality. Summary estimates for meta-analysis are provided as
95% confidence intervals.
Unit of analysis issues
Although we would have included cluster randomised trials, the
unit of randomisation in all of the included trialswas the individual
patient.
Dealing with missing data
Mortality results have been presented using denominators based
on the numbers of participants at randomisation (intention-to-
treat analysis). Generally, the results for other outcomes have been
presented using denominators based on the numbers of partici-
pants available at follow-up. In some cases, we investigated the
effect of drop outs and exclusions by conducting worst scenario
analyses for the primary outcomes, where those who were missing
to follow-up in the intervention group were assumed to have the
poorer outcome but not those who were missing in the control
group. We were alert to the potential mislabelling or non identifi-
cation of standard errors and standard deviations. Unless missing
standard deviations could be derived from confidence intervals or
standard errors, we did not assume values in order to present these
in the analyses.
Assessment of heterogeneity
Heterogeneity was assessed by visual inspection of the forest plot
(analysis) along with consideration of the chi² test for heterogene-
ity and the I² statistic (Higgins 2003).
Assessment of reporting biases
We considered there were insufficient data available to meaning-
fully assess publication bias by preparing a funnel plot. However,
our search of ’grey literature’, dogged pursuit of trials listed in
clinical trial registers and contact with trial authors should have
helped to avoid publication bias.
Data synthesis
Where appropriate, the results of comparable groups of trials were
combined using both fixed-effect and random-effects models, and
results presented with 95% confidence intervals.
Subgroup analysis and investigation of heterogeneity
Only subgroup analysis based on pre-existing nutritional status
was performed. To test whether the subgroups were statistically
significantly different from one another, we tested the interaction
using the technique outlined by Altman 2003.
Sensitivity analysis
We planned sensitivity analyses based on aspects of trial method-
ology. So far, we have explored the risk of bias associated with
inadequate concealment of allocation. To test whether the sub-
groups were statistically significantly different from one another,
we tested the interaction using the technique outlined by Altman
2003.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
Overall, of the 66 studies identified via the search strategy: 24 are
included, 36 are excluded, four are ongoing and two are awaiting
assessment.
Only 13 included trials were identified via the MEDLINE search
strategy. One further trial (Stableforth 1986), located via EM-
BASE, was indexed by MEDLINE, but was not retrieved by
the first two phases of the optimum Cochrane search strategy
for randomised controlled trials (Dickersin 1994; Higgins 2006).
BIOSIS yielded two further studies (Bean 1994; Brown 1992).
Gallagher 1992 was initially found from handsearching the Jour-
nal of Parenteral and Enteral Nutrition, but also appeared in
the reference list of another published trial. Bean 1994 and
Gallagher 1992 were only available as abstracts from conference
proceedings. The two presently unpublished trials (Hankins 1996;
Madigan 1994) and two previously unpublished trials (Duncan
2006; Espaulella 2000) were provided by personal contacts (Ian
Cameron, Heidi Guyer, Donna Duncan and Antony Johansen).
Bruce 2003, Houwing 2003 and Tidermark 2004 were initially
identified by handsearching Clinical Nutrition and Neumann
2004 by searchingNutrition. A separate examination of the search
strategy and findings prior to 2001 is available (Avenell 2001a).
All 24 included trials were published in English.
Included studies
Details of studymethods, population, interventions and outcomes
of individual trials are provided in the Characteristics of included
studies.
Further details (including clarifications) onmethodology, trial par-
ticipants and outcome, sought from all studies, were obtained
from trialists of 16 studies (Bastow 1983; Botella-Carretero 2008;
Brown 1992; Bruce 2003; Day 1988; Duncan 2006; Eneroth
2006; Espaulella 2000; Hankins 1996; Hartgrink 1998;Houwing
2003;Miller 2006;Neumann 2004; Sullivan 1998; Sullivan 2004;
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Tidermark 2004) and other sources for two trials (Ronald Koretz
for Gallagher 1992; Jane Robertson for Hoikka 1980).
Design
Twenty trials were randomised controlled trials, although seven of
these gave no details of the method of randomisation. The other
four trials (Bastow 1983; Brown 1992; Bruce 2003; Hoikka 1980)
were quasi-randomised trials. There were no cluster or cross-over
randomised trials.
Sample sizes
The 24 included studies involved a total of 1940 participants.
Sample size ranged from 10 participants in Brown 1992 to 318
participants in Duncan 2006.
Setting
The publication dates of the trials span 28 years, Hoikka 1980
being the earliest. Most of the trials were based in a single cen-
tre. Trials were conducted in eight countries (Australia, Finland,
the Netherlands, Spain, Sweden, Switzerland, UK, USA), with six
trials being conducted in the UK, four each in Australia and the
USA, and three in Switzerland.
Participants
The majority of participants were female, and in seven studies
(Bastow 1983; Bean 1994; Brown 1992; Bruce 2003; Duncan
2006; Stableforth 1986; Tidermark 2004) all participants were
female. Sullivan 1998 and Sullivan 2004 were the only studies
where male participants formed the majority. Where reported, the
mean age of participants was usually over 80 years. Gallagher 1992
gave no details on age, but the rest of the details provided in the
abstract were compatible with an older population. Only Bean
1994 applied an upper age limit, this being 85 years.
All studies (except Miller 2006 which included participants with
lower limb fractures) included only participants with hip frac-
ture. Separate data for participants with hip fracture have been
obtained for Miller 2006. Eleven studies (Day 1988; Delmi 1990;
Eneroth 2006; Espaulella 2000; Hartgrink 1998; Schürch 1998;
Stableforth 1986; Sullivan 1998; Sullivan 2004; Tidermark 2004;
Tkatch 1992) provided information on the types of hip frac-
tures suffered by the participants. Nine studies (Bastow 1983;
Bean 1994; Brown 1992; Delmi 1990; Eneroth 2006; Espaulella
2000; Schürch 1998; Tidermark 2004; Tkatch 1992) excluded
people with dementia or severe cognitive dysfunction. Many of
the studies excluded people with a wide range of medical condi-
tions. Seven studies (Day 1988; Duncan 2006; Espaulella 2000;
Hankins 1996; Houwing 2003; Sullivan 1998; Sullivan 2004) in-
dicated that consent (assent) was acceptable if given by a relative
or guardian.
Six studies, involving 363 participants, examined the effect of sup-
plementation on malnourished participants (Bastow 1983; Bean
1994; Brown 1992; Gallagher 1992; Hankins 1996;Miller 2006).
Only Gallagher 1992 defined participants as malnourished on the
basis of serum albumin; the remaining studies used anthropomet-
ric measurements, such as mid-upper arm circumference.
Interventions
The 24 included trials evaluated a variety of nutritional supple-
ments, mostly in comparison with a control group. Details of these
and the method of delivery in individual studies are provided in
the Characteristics of included studies. The comparisons under
test fell into five categories (as detailed below).
Madigan 1994 had three groups: the two supplemented groups
(one with a multivitamin and mineral supplement) were subse-
quently combined in the report, owing to small numbers at fol-
low-up. Since these two groups both fit the criterion in this re-
view for a “multinutrient” supplement group, the combined results
for these two groups, compared to the control, are also presented
here. Botella-Carretero 2008 also had three groups: oral protein
and energy, oral protein, and control; both supplemented groups
have been combined for this report, also owing to small numbers.
Miller 2006 had four groups: a nutrition supplementation group,
a physical activity intervention group, a combined intervention
group, and an attention control group. Only data from the nutri-
tion supplementation only and control groups are used here.
The following comparisons were made:
Multinutrient supplements (oral, nasogastric, intravenous)
versus control
The multinutrient supplements under test usually provided non-
protein energy, protein, some vitamins and minerals. These were
delivered either orally, via a nasogastric tube, intravenously, or
combinations of these.
Oral supplements
Ten studies (Botella-Carretero 2008; Brown 1992; Bruce 2003;
Delmi 1990; Hankins 1996; Houwing 2003; Madigan 1994;
Miller 2006; Stableforth 1986; Tidermark 2004) involved 538
participants.
Nasogastric tube feeding
Four studies (Bastow 1983; Gallagher 1992; Hartgrink 1998;
Sullivan 1998) involved 377 participants.
Nasogastric tube feeding and oral supplements
One study (Sullivan 2004) involved 57 participants.
Intravenous feeding and oral supplements
One study (Eneroth 2006) involved 80 participants.
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High protein containing supplements versus low-protein or
non-protein containing supplements
Protein supplementation was delivered within oral feeds.
Four studies (Espaulella 2000; Neumann 2004; Schürch 1998;
Tkatch 1992) involving 371 participants. Whereas the protein
supplement resulted in extra calories in the intervention group
in Tkatch 1992, the energy content of both intervention and
placebo groups were equivalent in Espaulella 2000 and Schürch
1998.Moderate quantities of minerals and vitamins were also pro-
videdwith the protein supplement in Espaulella 2000 and Schürch
1998; nonewere in sufficient doses to detract from these being pre-
dominantly protein supplements. In Neumann 2004 there were
differences in vitamin and mineral intakes between the high- and
lower-protein supplements, and the carbohydrate intake in the
lower-protein supplement resulting in similar energy contents of
the two supplements.
Vitamin supplement versus control
Two studies (Day 1988; Hoikka 1980) involved 97 participants.
Day 1988 investigated the intravenous thiamin (vitamin B1) and
water soluble vitamins versus control. Hoikka 1980 investigated
the use of oral vitamin D versus control.
Isonitrogenous ornithine alpha-ketoglutarate versus peptide
supplement
Ornithine alpha-ketogluturate is metabolised in part to the amino
acid glutamine, and is used to improve nitrogen conservation.
The interventions were probably delivered orally.One study (Bean
1994) involved 59 participants.
Dietetic assistants versus usual care
Provision of extra assistance in the form of dietetic assistants, above
that of dietitians and nurses, to help improve people’s dietary in-
take. One study (Duncan 2006) involved 318 participants.
Excluded studies
The reasons for excluding 36 studies are given in the
Characteristics of excluded studies. Six excluded studies were pub-
lished in languages other than English, sufficient translation hav-
ing been obtained to establish non-eligibility.
Ongoing studies
Details of four ongoing trials are given in the Characteristics of
ongoing studies.
Studies awaiting classification
Details of the two studies in this category are given in the
Characteristics of studies awaiting classification. Requests for fur-
ther details have been sent to the trial investigators.
New studies found this update
Of the 10 newly identified studies for this update, one new trial
is included (Botella-Carretero 2008), five trials are excluded (
Boudville 2002; Hommel 2007; Thomas 2008 ; Kacmaz 2007;
Oloffson 2007), one awaits classification, pending further infor-
mation from the trial investigators (Gerstorfer 2008), and three
trials are ongoing (Dagnelie; Houdijk; Miller). One former ongo-
ing trial is now included (Eneroth 2006); as is one trial formerly
awaiting classification (Miller 2006).
Risk of bias in included studies
The quality of trial methodology, as reported, was disappoint-
ing and risk of bias associated with poor trial methods could not
be ruled out. Many of the trials failed to report trial methodol-
ogy in sufficient detail to give top scores on individual items (see
Table 1 for scoring scheme and Table 2 for results). The impres-
sion that the scores for these studies more reflect the quality of
reporting rather than trial methodology was strengthened by the
changed, generally increased, scores of some items of eight stud-
ies upon gaining additional information from the trialists (Brown
1992; Bruce 2003; Day 1988; Espaulella 2000; Hankins 1996;
Hartgrink 1998; Houwing 2003; Sullivan 1998).
Table 2. Methodological quality assessment: results for individual trials
Com-
parison
Items (defined in Table 1)
Study
ID
a b c d e f g h i j k
1. Multinutrient supplement (oral, nasogastric, intravenous)versus control
a. Oral supplements
Botella-Car-
retero
2008
2 1 0 2 0 2 2 0 0 2 1
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Table 2. Methodological quality assessment: results for individual trials (Continued)
Brown
1992
0 2 2 1 0 2 0 0 0 1 0
Bruce
2003
0 1 0 2 1 2 2 0 0 1 2
Delmi
1990
1 1 0 2 0 2 2 0 0 2 2
Hankins
1996
2 2 0 2 1 2 2 0 0 2 1
Houwing
2003
2 2 1 2 0 2 1 1 1 1 0
Madi-
gan
1994
1 0 0 0 0 2 1 0 0 2 1
Miller
2006
2 2 2 1 0 2 2 0 0 1 1
Stable-
forth
1986
1 1 0 0 2 2 1 0 0 2 0
Tider-
mark
2004
1 2 0 1 2 2 0 0 0 2 2
b. Nasogastric tube feeding
Bastow
1983
0 2 0 1 1 2 1 0 0 1 0
Gal-
lagher
1992
1 0 0 0 0 2 1 0 0 0 0
Hart-
grink
1998
1 1 0 2 2 2 2 0 0 2 0
Sullivan
1998
2 2 0 0 0 2 2 0 0 2 2
c. Nasogastric tube feeding and oral supplements
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Table 2. Methodological quality assessment: results for individual trials (Continued)
Sullivan
2004
2 2 0 0 0 2 1 0 0 2 2
d. Intravenous feeding and oral supplements
Eneroth
2006
1 2 0 1 2 2 2 0 0 2 1
2. High protein containing supplement versus low protein or non-protein containing supplement
Es-
paulella
2000
2 1 2 2 2 2 2 2 2 2 2
Schürch
1998
1 1 0 2 0 2 2 2 1 2 2
Tkatch
1992
1 0 0 1 0 2 2 1 0 2 2
Neu-
mann
2004
1 1 0 2 0 2 2 1 1 1 1
3. Vitamin supplement versus control
a. Thiamin (vitamin B1) and water soluble vitamins
Day
1988
1 2 2 1 2 2 2 0 0 2 1
b. Vitamin D
Hoikka
1980
0 0 0 0 0 2 1 1 1 1 2
4. Isonitrogenous ornithine alpha-ketoglutarate versus peptide supplement
Bean
1994
1 2 0 0 0 2 1 2 2 2 2
5. Dietetic assistants versus usual care
Duncan
2006
2 1 2 2 1 1 2 0 0 1 1
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Allocation concealment
Concealment of allocation (item a) was confirmed in seven trials (
Botella-Carretero 2008; Duncan 2006; Espaulella 2000; Hankins
1996;Miller 2006; Sullivan 1998; Sullivan 2004) that used sealed,
opaque envelopes and in Houwing 2003, which used computer
generated allocation applied independently of the main trial in-
vestigator. Though numbered sealed and opaque envelopes were
used in Tidermark 2004, the preparation and opening of these was
by the same person. Similarly, there was no report of safeguards
in Eneroth 2006, where closed envelopes were administered by
a research nurse. Allocation was unlikely to be concealed in the
four quasi-randomised studies (Bastow 1983; Brown 1992; Bruce
2003; Hoikka 1980). Of the remaining 10 trials, three gave in-
complete details and seven gave no details at all of the randomisa-
tion process.
Intention-to-treat analysis
Although not usually explicitly stated in the methods sections,
intention-to-treat analysis (item b) was carried out in 11 stud-
ies (Bastow 1983; Bean 1994; Brown 1992; Day 1988; Eneroth
2006;Hankins 1996;Houwing 2003;Miller 2006; Sullivan 1998;
Sullivan 2004; Tidermark 2004). In four studies, participants were
excluded after randomisation because of poor compliance with di-
etary supplementation (Espaulella 2000; Hankins 1996; Madigan
1994; Tkatch 1992); data on some of these participants were later
obtained from Hankins 1996 and Espaulella 2000.
Blinding
Of the eight studies where blinding of participants (item h)
and treatment providers (item i) was theoretically practical (Bean
1994; Day 1988; Espaulella 2000; Hoikka 1980; Houwing 2003;
Neumann 2004; Schürch 1998; Tkatch 1992), only two (Bean
1994; Espaulella 2000) confirmed that participants and treatment
providers were blinded to the intervention. Hoikka 1980 claimed
to be double-blind but failed to clarify to whom this applied. Dif-
ferences in the look and taste of active and placebo supplements in
Houwing 2003 may have prevented effective blinding of outcome
assessment. Neumann 2004 claimed to be double-blind but pro-
vidednodetails onhow thiswas achieved.Whilst blinded outcome
assessment (item c) is difficult for some interventions such as those
involving the use of a nasogastric tube, it should be possible for
other interventions, and becomes easier after the intervention has
ended. This was the case in point for Duncan 2006, where there
was blinded assessment of the trial participant’s progress through
rehabilitation.
Baseline comparability
Although 17 trials had comparability of the groups at baseline
(item d) or only a small chance of confounding, details of the nu-
tritional status of the groups were often missing. Related to this is
the lack of information on anthropometric parameters. While it
is difficult to measure height and weight in people with hip frac-
ture, seven trials failed to provide information about any baseline
anthropometry; for example, mid-upper arm circumference, or
weight. An appraisal of the trials for baseline imbalances in the nu-
tritional risk revealed only a reported imbalance in weight, where
participants receiving supplementation were on average heavier,
in Stableforth 1986. However, body mass index, which is a more
relevant measure of nutritional status than weight, was not avail-
able for this trial.
Care programme comparability
Only six trials (Day 1988; Eneroth 2006; Espaulella 2000;
Hartgrink 1998; Stableforth 1986; Tidermark 2004) reported or
provided confirmatory evidence that care programmes (item e)
were the same in both intervention and control groups.
External validity and outcome assessment
Inclusion and exclusion criteria (item f) were well defined in these
trials.
Fifteen studies (Botella-Carretero 2008; Bruce 2003; Day 1988;
Delmi 1990; Eneroth 2006; Espaulella 2000; Hankins 1996;
Hartgrink 1998; Hoikka 1980; Madigan 1994; Miller 2006;
Neumann 2004; Schürch 1998; Sullivan 1998; Tkatch 1992) gave
clear details of the exact nutritional content of the nutrients ad-
ministered and of the protocol for application of the supplement
(item g).
Follow-up of trial participants was generally active and appropriate
(item j) in terms of outcome assessment.
Recovery from hip fracture in older people takes time, with long
term implications for morbidity and functional status. The dura-
tion of surveillance (item k) was not clearly defined in four studies
(Bastow 1983; Botella-Carretero 2008; Brown 1992; Gallagher
1992) and was generally too short, with seven studies following
participants up for less than three months. Eleven studies followed
up participants for six months or over; Schürch 1998 and Miller
2006 followed up participants for one year.
Effects of interventions
The outcomes reported in the included studies are listed in the
Characteristics of included studies. These are grouped by ’main’
(primary and secondary) outcomes and ’other’ outcomes, as de-
fined in the Types of outcome measures. The results presented
here concentrate on main outcomes.
The included studies often failed to report main outcomes. For
example, only one trial (Tidermark 2004) reported participants’
perceived quality of life after discharge and on fracture healing.
Though in the ’other’ outcomes category, it was notable that carer
burden and stress, and economic outcomes were also not reported.
Postoperative complications were reported as a wide variety of in-
dividual conditions (including diarrhoea, nausea, vomiting, aspi-
ration pneumonia, gastrointestinal ulcer, pressure sore, face flush-
ing, deep hip joint infection, chest infection, urinary tract in-
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fection, deep venous thrombosis, pulmonary embolism, throm-
bophlebitis, ischaemic heart disease, cardiac failure, anaemia, hy-
ponatraemia, confusion, anaphylaxis, and acute renal failure) and
generic complications (gastrointestinal, surgical, infection, post-
operative, life-threatening). Those presented for individual studies
are noted in the Characteristics of included studies. In order to
give a more complete picture of morbidity, we opted to present
the number of participants with complications at the end of indi-
vidual studies. Results were not used from those studies, such as
Tkatch 1992, which provided the numbers of complications but
not the numbers of participants with complications. Results from
Houwing 2003 were also not pooled since this trial only recorded
pressure sores.
Where possible, the numbers of trial participants with ’un-
favourable outcome’ have been presented. As defined above, this
is the sum of the participants who had died plus the survivors with
complications. For most studies, this result could not be deduced
from the available data. Results for ’unfavourable outcome’ based
on a slightly different definition (mortality or survivors with a ma-
jor complication or two or more minor complications) originally
presented in Delmi 1990, were available for three studies (Delmi
1990; Hankins 1996; Tkatch 1992) and are used in this review.
Mortality results have been presented using denominators based
on the numbers of participants at randomisation (intention-to-
treat analysis). Generally, the results for other outcomes have been
presented using denominators based on the numbers of partici-
pants available at follow-up. Exceptions to this are noted below.
Lengths of hospital stay in the acute hospital and rehabilitation
hospital were often reported but have not been presented in the
analyses, or pooled. This is because, even when means and stan-
dard deviations (SD) for these outcomes have been reported, it is
unlikely that lengths of stay were normally distributed.
In the following, results are presented for the fixed-effect model.
Where the conclusions reached by combining comparable groups
of trials differed noticeably between the fixed-effect and random-
effects models, the results for the random-effects models are also
presented.
Multinutrient supplements (oral or nasogastric
routes, or both) versus control
Belowwe present the separate results by the route (oral, nasogastric
or both) used for multinutrient supplementation, and then dis-
cuss the overall results for multinutrient supplementation. Finally,
we investigate whether the results varied, according to whether
the trials specifically targeted people who were malnourished, or
according to trial quality (represented by the whether allocation
was concealed or not).
Oral supplements
Ten studies evaluated the effect of oral multinutrient supplemen-
tation (Botella-Carretero 2008; Brown 1992; Bruce 2003; Delmi
1990; Hankins 1996; Houwing 2003; Madigan 1994; Miller
2006; Stableforth 1986; Tidermark 2004) of which three (Brown
1992; Hankins 1996; Miller 2006) targeted people who were
malnourished. Pooling of the mortality data from nine studies (
Houwing 2003 did not provide mortality data) showed no statis-
tically significant difference between the two groups in mortality
(see Analysis 1.1: risk ratio (RR) 0.76, 95% confidence interval
(CI) 0.42 to 1.37). Bruce 2003 reported similar percentages of
participants in the two groups who had died or were in a nursing
home at six months (23.4% versus 24.6%).
Six studies (Botella-Carretero 2008; Delmi 1990; Hankins 1996;
Madigan 1994; Stableforth 1986; Tidermark 2004) reported the
numbers of participants with complications at the end of the study.
Results from Houwing 2003 were not included since these were
only for pressure sores: there was no statistically significant dif-
ference between the two groups in the numbers of participants
with this complication. Pooled results from six studies showed a
reduction, which was not statistically significant, in the partici-
pants with complications in the supplemented group (see Analysis
1.2: RR 0.81, 95% CI 0.58 to 1.13).
Although data pooled using the fixed-effect model from four trials
for the combined outcome for mortality or complications (’un-
favourable outcome’) at final follow-up tended to favour the sup-
plemented group (see Analysis 1.4: RR 0.76, 95% CI 0.55 to
1.04), there was significant heterogeneity (Chi² = 4.84, df = 2 (P
= 0.09); I² = 59%). The pooled results using the random-effects
model showed no statistically significant difference (see Analysis
1.5: RR 0.71, 95% CI 0.41 to 1.22). Delmi 1990 presented re-
sults, without explanation of the missing participants, for only
52 participants out of the 59 originally randomised. Exploratory
analyses based on numbers randomised (in all trials where avail-
able) in which it was assumed that all excluded participants in
the supplemented group had complications at follow-up, for ’un-
favourable outcome’ (see Analysis 1.6: RR 0.85, 95% CI 0.62 to
1.15) again showed no statistically significant difference between
the two groups.
Hankins 1996 also presented data for ’unfavourable outcome’ in
the acute hospital (seeAnalysis 1.6: RR 0.96, 99%CI 0.64 to 1.44)
and post discharge (see Analysis 1.6: RR 1.10, 99% CI 0.39 to
3.09). Delmi 1990 presented data for similar outcomes but gave
insufficient explanation of the denominators used in their report.
The duration of hospital stay was reported in eight studies. The
data for those trials that allowed significance testing are presented
in Table 3. Botella-Carretero 2008 reported that hospital stay was
similar for all three groups (the graph of these data clearly showed
no statistically significant differences). Brown 1992 reported a
lower acute hospital stay for the supplementation group (27 days
versus 48 days: mean difference -21.00 days, 99% CI -65.15 to
23.15 days). Bruce 2003 reported no significant difference be-
tween the two groups in the mean length of hospital stay (17.7
days versus 16.6 days: mean difference 1.10 days, 99%CI -3.53 to
5.73 days). Delmi 1990 reported a statistically significantly lower
median length of stay in acute and rehabilitation wards for the
13Nutritional supplementation for hip fracture aftercare in older people (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
supplementation group (24 days (range 13 to 157) versus 40 days
(range 10 to 259); reported P < 0.02). Hankins 1996 found that
supplemented participants had a median acute and rehabilitation
stay of 26 days (range 6 to 60) versus 21 days (range 3 to 60) for
participants in the control group (reported P = not significant).
Madigan 1994 found that the acute hospital stay was 16 days
in the combined intervention group and 15 days in the control
group (mean difference 1.00 day, 99% CI -8.51 to 10.51 days).
Both groups, including several patients with other lower-limb frac-
tures, in Miller 2006 stayed a median of 24 days for in hospital.
Tidermark 2004 reported no significant difference in median hos-
pital stay during the first year after surgery in intervention and
control groups (20 days (range 5 to 356 days) versus 27 days (range
5 to 197 days)).
Table 3. Length of hospital stay data used for significance testing
Study ID Intervention
(n, mean, sd)
Control
(n, mean, sd)
Mean difference (99% confidence inter-
vaI)
Oral supplements
Brown 1992 5 27.00 10.00 5 48.00 37.00 -21.00 days (-65.15 to 23.15)
Bruce 2003 50 17.70 9.40 58 16.60 9.20 1.10 days (-3.53 to 5.73)
Madigan
1994
18 16.00 8.00 12 15.00 11.00 1.00 day (-8.51 to 10.51)
Nasogastric tube feeding
Sullivan 1998 8 38.20 36.90 7 23.70 20.00 14.50 days (-24.34 to 53.34)
High protein supplements
Espaulella
2000
85 16.40 6.60 86 17.20 7.70 -0.80 days (-3.62 to 2.02)
Neumann
2004
18 23.20 5.52 20 28.00 11.63 -4.80 days (-12.29 to 2.69)
Vitamin B1
Day 1988 28 35.00 34.00 30 29.00 30.00 6.00 days (-15.75 to 27.75)
sd: standard deviation
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Bruce 2003 reported no significant differences between the
two groups in functional outcomes (fall in the Katz activities of
daily living score: 41.7% versus 33.9%) or living at home at six
months (63.8% versus 63.2%). Hankins 1996 found no statisti-
cally significant effect of the supplement at two months on the
Barthel Index of functional ability; median 56 (range 0 to 100)
versus 40 (range 0 to 92). Madigan 1994 found that the combined
intervention group were more likely to return to their premorbid
mobility (non-return: 9/18 versus 7/12; RR 0.86, 99% CI 0.36
to 2.05; analysis not shown), but this may have related to the fact
that significantly more supplemented participants were sent to a
rehabilitation hospital. Activities of daily living, assessed by the
Katz score, in Tidermark 2004, were better maintained in the sup-
plemented group at six months (dependence in bathing and one
other function: 2/18 versus 8/16; RR 0.22, 99% CI 0.04 to 1.39;
analysis not shown) but less so at 12 months (4/18 versus 6/16;
RR 0.63, 99% CI 0.15 to 2.59; analysis not shown), compared
with the control group. Tidermark 2004 also found that mobility
data were not significantly different between the two groups.
Tidermark 2004 reported no significant difference between the
two groups for health related quality of life at six and 12 months,
as assessed by the EuroQol questionnaire.
Tidermark 2004 found no significant difference between the two
groups in fracture healing complications (4/18 versus 7/17; RR
0.54, 99% CI 0.14 to 2.10; analysis not shown).
Botella-Carretero 2008 reported mean consumption of 41% for
the protein supplement and 51% for the protein and energy sup-
plement. Bruce 2003 reported a mean consumption of 20.6 cans
of supplement, out of a maximum possible of 28. Delmi 1990
reported that the supplement did not reduce volitional food in-
take, and compliance appeared not to be a problem.Hankins 1996
found that only 65% of participants managed to complete the
full 30 days of supplementation, however, the supplement had no
significant effect on ordinary food intake. Houwing 2003 found
that the mean daily intake of the active or placebo supplements
was 77% in both groups. Madigan 1994 also found that the oral
supplement did not significantly affect volitional intake, but made
no comment on compliance. Neither Brown 1992, Tidermark
2004 nor Stableforth 1986 gave details on volitional food intake
or compliance with the supplements. Specific data on adherence
for participants with hip fracture in the nutrition-supplementa-
tion only group of Miller 2006 were not available.
Nasogastric tube feeding
Four studies examined nasogastric multinutrient supplementation
(Bastow 1983; Gallagher 1992; Hartgrink 1998; Sullivan 1998).
Gallagher 1992, which was only published as an abstract, gave
no denominators and so could not be included in the meta-anal-
yses. Information provided by Ronald Koretz (personal commu-
nication), based on notes taken at a conference presentation by
Gallagher 1992, indicated a possible failure to undertake inten-
tion-to-treat analysis. It seems likely that 12 participants allocated
to the intervention group, who had feeding discontinued when
their tube was pulled out, were crossed over to the control group
in the analysis. There were also some differences in the results pre-
sented at the conference and in the published abstract.
Gallagher 1992 gave no information on deaths in the published
abstract; two deaths were reported in the conference presentation.
Pooling of mortality data from the other three studies showed no
evidence of an effect (see Analysis 1.1: RR 0.99, 95% CI 0.50
to 1.97). However considerable heterogeneity for mortality exists
between the studies (chi² = 6.44, P = 0.04; I² = 68.9%). All seven
deaths in Hartgrink 1998 occurred in the intervention group dur-
ing the two-week period of observation. This could have been due
to chance, as the deaths were not obviously related to tube feeding
(anaesthetic death, cardiac arrest, stroke and multi-organ failure),
and did not appear to relate to aspiration pneumonia, a complica-
tion of tube feeding. Four of the deaths occurred in participants in
whom tube feeding had not started, although the tube had been
placed. It was evident that tube feeding was poorly tolerated, with
only 26% of the intervention group tolerating feeding for the full
two weeks. Conversely all five deaths occurred in the control group
in Sullivan 1998; this might in part reflect the greater frailty of the
control group at recruitment.
The four trials were heterogeneous in the nutritional status of the
study participants. Unlike Hartgrink 1998, Bastow 1983 targeted
nasogastric feeding on thin and very thin participants, defined by
anthropometry. Seventy-eight per cent of participants tolerated
nasogastric feeding until discharge from the ward, although 18 in
the intervention group developed diarrhoea, which was ascribed
to antibiotics in 16. Bastow 1983 did not report gastrointestinal
complications in the control group. Hospital mortality was re-
duced in the very thin group (2/25 versus 5/25; RR 0.37, 99% CI
0.05 to 2.78) rather than in the thin group (5/39 versus 4/35; RR
1.12, 99% CI 0.22 to 5.67); analyses not shown (test for interac-
tion based on 95% CI: P = 0.27). Malnourished participants were
not specifically targeted in Sullivan 1998. In Sullivan 1998, the
intervention group received supplements until discharge or until
a good oral intake was achieved. Patients with low serum albumin
readings, described as malnourished, were targeted in Gallagher
1992.
Only Sullivan1998 provideddata onparticipants developingmed-
ical complications in intervention and control groups (see Analysis
1.2: RR 1.09, 99%CI 0.64 to 1.86), and no study provided infor-
mation on ’unfavourable outcome’. Sullivan 1998 reported that
three out of eight in the intervention group had bloating in the
early morning and none in the control group; there was no feed-
induced diarrhoea. Sullivan 1998 did not report on aspiration
pneumonia.
Three studies provided information on length of hospital stay. In
the published abstract, Gallagher 1992 found that rehabilitation
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length of stay was 25 days in the intervention group and 33 days
in the control group (reported P = 0.058). However, in the notes
taken from the conference presentation by Gallagher 1992, the
length of stay was 22.7 days for the control group and 22.6 days
for the intervention group. Sullivan 1998 reported no significant
difference between the two groups in the length of acute care
stay for survivors (38.2 days versus 23.7 days: mean difference
14.50 days, 99% CI -24.34 to 53.34 days). Bastow 1983 stated
the median length of stay for the very thin group only (including
those who died): a median of 29 days for the intervention group
and 38 days for the control group (reported P = 0.04). Hartgrink
1998 gave no information about length of stay but reported that
the intervention group were less likely to have left hospital by two
weeks (still in hospital at two weeks: 55/62 versus 53/67; RR 1.12,
99% CI 0.92 to 1.37; analysis not shown).
Where reported, physiotherapy goals were achieved more quickly
in the intervention groups: Gallagher 1992 (published abstract),
12.7 days versus 16.2 days (reported P = not significant); Bastow
1983 thin group: 10 days (range 4 to 20) versus 12 days (range
5 to 26) (reported P = 0.04); Bastow 1983 very thin group: 16
days (range 5 to 34) versus 23 days (range 10 to 45) (reported P =
0.02). Sullivan 1998 showed no statistically significant difference
between intervention and control groups for activities of daily
living at discharge (Katz index (0 = independent to 12 = totally
dependent): 4.1 versus 5.9; mean difference -1.80, 99% CI -7.17
to 3.57).
Sullivan 1998 found that volitional food intake was not signif-
icantly affected by nasogastric feeding. Bastow 1983 found that
nasogastric feeding significantly suppressed oral intake in the thin
group but not in the very thin group. The suppression of food in-
take in the thin group amounted to 1.1 MJ, compared with daily
nasogastric feeding which provided 4.2 MJ.
Nasogastric tube feeding and oral supplements
Sullivan 2004 evaluated nightly nasogastric feeding tailored to
the calculated energy requirements of individual participants af-
ter taking account of the intake from meals. If the difference be-
tween calculated requirements and food intake decreased to 240-
480 kcal/day participants were asked to drink one or two cans of
the supplement orally instead of nasogastric feeding. This regi-
men was compared with standard care. At six months there were
no statistically significant differences between the two groups in
mortality (see Analysis 1.1: RR 0.74, 99% CI 0.16 to 3.37) or post
operative complications (see Analysis 1.2: RR 1.11, 99% CI 0.66
to 1.87).
There was no significant difference in hospital length of stay. The
median (interquartile range) length of hospital stay for the inter-
vention group was 9 days (7 to 21) and for the control group 9
days (7 to 15), reported P = 0.817).
Sullivan 2004 found no significant differences between interven-
tion and control groups in the Katz Index of activities of daily
living scores on discharge (median (interquartile range): 8 (4 to
11) versus 9 (7 to 11); reported P = 0.503), or the rate of discharge
to an institution (25/27 versus 27/30; RR 1.03, 99% CI 0.83 to
1.27; analysis not shown).
Five of the 27 intervention group participants never started tube
feeding because of either refusal of tube placement or lack of tol-
eration of the feeding tube. Targeted tube feeding was continued
until the oral intake was deemed to be adequate in only five of
the remainder, and only two participants required no tube rein-
sertions. Though there was no significant difference between the
two groups in the incidence of diarrhoea (5/27 versus 3/30; RR
1.85, 99% CI 0.32 to 10.68; analysis not shown), Sullivan 2004
reported that the diarrhoea in the intervention group was more
difficult to control. In the first week, the intervention group met
86% of their calculated energy requirements compared with 63%
for the control group (reported P = 0.002); the difference between
the two groups was not significant for the 22 trial participants as-
sessed in the second week (96% versus 95%; reported P = 0.942).
Intravenous feeding and oral supplements
Eneroth 2006 evaluated three days of intravenous feeding followed
by seven days of oral supplements compared with standard care.
Mortality was not significantly reduced (see Analysis 1.1: RR 0.11,
99% CI 0.00 to 4.95), but there was a significant reduction in
participants with complications (see Analysis 1.2: RR 0.21, 99%
CI 0.08 to 0.59). Themean length of hospital stay for both groups
was 12.5 days. There was no significant difference between the
two groups for those who were discharged to their own homes
(14/40 versus 22/40, RR 0.64, 99% CI 0.33 to 1.24; analysis not
shown).
Multinutrient supplements - overall results
Overall mortality from pooling the results of oral, nasogastric and
intravenous multinutrient supplementation studies was similar in
the intervention and control groups (see Analysis 1.1: RR 0.77,
95% CI 0.51 to 1.15).
The number of participants with complications was reduced in
intervention compared with control groups when using the fixed-
effect model (see Analysis 1.2: RR 0.71, 95% CI 0.57 to 0.89).
However there was substantial heteogeneity for this outcome (I²
= 70%, chi² = 23.63, P = 0.001). The result using the random-
effects model was no longer statistically significant (see Analysis
1.3: RR 0.73, 95%CI 0.47 to 1.12). The significant heterogeneity
was completely lost by removing Eneroth 2006 (I² = 0%, chi² =
5.63, P = 0.47) and yielded a non-effect (RR 0.99; 95% CI 0.32
to 10.68) from the pooled results of the remaining seven trials;
analysis not shown.
There were no data from nasogastric groups or intravenous groups
on ’unfavourable outcome’ (see Analysis 1.4).
Subgroup and sensitivity analysis
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Nutritional status of trial populations
Subgrouping the trials according to whether they targeted mal-
nourished participants showed a potential benefit in terms of mor-
tality for supplementation in those which targeted malnourished
participants (see Analysis 2.1: RR 0.52, 95% CI 0.25 to 1.07).
Both visually and based on I² statistics, there was some indication
of low to moderate heterogeneity (I² = 32%; chi² = 10.29, P =
0.17) in the subgroup of trials that did not target malnourished
participants (RR 0.92, 95%CI 0.56 to 1.53). However, the results
of the groups were not statistically significantly different from each
other (test for interaction: two tailed z-test = 0.21) and thus there
is no evidence to confirm that malnourished participants are more
likely to benefit. The analyses for complications (see Analysis 2.2)
and ’unfavourable outcome’ (see Analysis 2.3) are also presented,
but the greatly reduced available data for people who were mal-
nourished limit their usefulness.
Methodological quality
In previous versions of the review, we subgrouped the results for
mortality according to the overall score for the methodological
quality of individual trials. This gave inconclusive results but in
recognition of the lack of evidence of a relationship between valid-
ity and summary scores (Juni 1999) we decided to test instead the
effects of whether allocation was concealed or not. The results for
mortality subgrouped by whether allocation was concealed (Risk
of bias table: Yes) or may have been concealed but insufficient in-
formation was available (Unclear) or was not concealed as in the
use of quasi-randomised methods (No) are presented in Analysis
3.1. A test for interaction confirms the visual impression that the
pooled results of the four trials with confirmed allocation conceal-
ment are not statistically significantly different from those of the
three trials where allocationwas not concealed (test for interaction:
two tail z-test = 0.23). However, a test of interaction shows the re-
sults of the trials with confirmed allocation concealment and those
of trials where the status of concealment is unclear are statistically
significantly different from each other (two tail z-test = 0.03). The
’unclear concealment’ group is clearly heterogenous (chi² = 8.36,
P = 0.08; I² = 52%) and we think it is inadvisable to draw any
conclusions from the above test of interaction result.
High protein containing supplements versus low-
protein or non-protein containing supplements
Three studies (Espaulella 2000; Schürch 1998; Tkatch 1992) in-
vestigated whether approximately 20 g of protein provided within
an oral supplement on a daily basis influenced outcome from
hip fracture. Neumann 2004 investigated whether an high-pro-
tein supplement providing an extra 12.2 g or more of protein
(with some differences in vitamins and minerals also) influenced
outcome. All four studies failed to carry out intention-to-treat
analyses (although information was later provided on mortality
and hospital complications of excluded participants in Espaulella
2000). Denominators are sometimes missing or unclear. Tkatch
1992 excluded some of the intervention group for poor compli-
ance with supplement taking, whilst some of the controls were
excluded for later taking a dietary supplement. Espaulella 2000
excluded five people from the intervention group and three from
the control group for protocol violations, and two from the con-
trol group because they were unable to swallow. Thus, unavoid-
ably, the results presented here are not intention-to-treat analy-
ses. No significant effect on mortality could be demonstrated (see
Analysis 4.1: RR 1.42, 95% CI 0.85 to 2.37). An ’unfavourable
outcome’ (for Espaulella 2000: death or complication by the end
of the study; for Tkatch 1992: death by the end of the study or,
for survivors, a major complication or two or more minor compli-
cations present at the end of the study) was significantly reduced
by protein supplementation (see Analysis 4.2: RR 0.78, 95% CI
0.65 to 0.95); this outcome was not reported by Schürch 1998.
An exploratory analysis looking at the effect of assuming that all
excluded participants in the protein supplementation group had
an ’unfavourable outcome’ could not be undertaken. However the
results for Espaulella 2000 should be viewed in the context of the
greater number of deaths in the protein supplementation group.
In Tkatch 1992, neither the results for unfavourable outcome in
acute hospital (9/33 versus 13/29; RR 0.61, 99% CI 0.25 to 1.50)
nor in rehabilitation hospital (4/19 versus 14/22; RR 0.33, 99%
CI 0.10 to 1.12) were statistically significant; analyses not shown.
None of the four trials provided sufficient information to evaluate
numbers of participants with complications at the end of the study.
Espaulella 2000 reported that 44 out of 61 in the intervention
group and 57 of 67 in the control group developed at least one
complication during the six months of the study (RR 0.85, 99%
CI 0.66 to 1.08; analysis not shown). Neumann 2004 reported
that there were no differences between the groups for complica-
tions or adverse events.
Espaulella 2000 reported an acute hospital stay of 16.4 days in
the intervention group and 17.2 days in the control group (mean
difference -0.80 days, 99% CI -3.62 to 2.02 days). Tkatch 1992
reported a statistically significantly (P < 0.05) lowermedian length
of acute and rehabilitation hospital stay in the intervention group
(combined stay: median 69.4 days versus 101.6 days; acute hospi-
tal stay: median 23.5 days versus 24.7 days; rehabilitation hospital:
78.6 days versus 91.8 days). Schürch 1998 reported mean figures
of 18.0 days versus 16.9 days on the acute ward, and median stays
of 33 versus 54 days in the rehabilitation ward (reported differ-
ence 21 days, 95% CI 4 to 25 days; P = 0.018). Neumann 2004
reported the rehabilitation stay was not significantly different be-
tween the two groups (23.2 days versus 28.0 days; mean difference
-4.80 days, 99% CI -12.29 to 2.69 days). Neumann 2004 also
reported no significant difference in the destination at discharge
between the two groups.
Espaulella 2000 found no difference between intervention and
control groups for mobility or Barthel Index scores six months
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after recruitment. Schürch 1998 also reported non-significant im-
provements in biceps muscle strength and activities of daily living
score at six months; these were not reported as being measured
by Tkatch 1992. Schürch 1998 reported that seven participants
in the intervention group and 13 in the control group developed
vertebral deformities after one year. Again denominators were not
given, and the difference was said to be not statistically significant.
Neumann 2004 found no significant difference between groups
for themobility subscale of the Functional Independence Measure
at any time point including at three months post discharge.
Neither Schürch 1998 nor Tkatch 1992 gave information about
the effect of the supplements on voluntary food intake. Espaulella
2000 reported that 64.7% (55/85) of the intervention group and
74.4% (64/86) of the control group had good consumption of the
supplement. Neumann 2004 reported that participants had 19.8
days of the high-protein supplement, compared with 21.1 days
for the lower-protein supplement. They found that energy intakes
were not significantly different between the groups, but that the
high-protein group also had significantly greater daily intakes of
dietary fibre, vitamin C and polyunsaturated fatty acids.
Vitamin supplements versus control
Day 1988 tested whether intravenous thiamin (vitamin B1) and
other water soluble vitamins influenced postoperative mental
function in participants. The daily dose of thiamin (250 mg) pro-
vided over 300 times the UK reference nutrient intake for this
vitamin, that of riboflavin, 3.6 times, of pyridoxine, 42 times, of
nicotinamide and ascorbic acid, 13 times. Sixty-one per cent of the
intervention group and 75% of the control group had satisfactory
thiamin status at baseline. There was no significant difference in
mortality (see Analysis 5.1: RR 1.37, 99% CI 0.33 to 5.62) or in
the numbers of participants with complications (see Analysis 5.2:
RR 1.32, 99% CI 0.65 to 2.69). Likewise, the incidence of acute
postoperative confusion, the primary outcome of Day 1988, did
not differ between the two groups (11/28 versus 12/32; RR 1.05,
99% CI 0.45 to 2.44; analysis not shown). The length of hospital
stay was not affected (mean difference 6.00 days, 99% CI -15.75
to 27.75 days), and residence at final follow-up was reported not
to be affected by the intervention.
Hoikka 1980 compared oral 1-alpha-hydroxycholecalciferol (an
active form of vitamin D) and 1 g calcium carbonate versus 20 g
calcium carbonate in 37 participants with hip fracture. No data
frommain outcomes were reported, except for complications. Six,
including two severe cases, out of 19 in the intervention group
and two out of 18 in the control group developed hypercalcaemia
(see Analysis 6.1: RR 2.84, 99% CI 0.41 to 19.48). Hoikka 1980
reported that there was no effect on hand muscle strength or bone
mineral density (despite significant increases in bone alkaline phos-
phatase at three months suggesting healing) over the six months
post-fracture observation period.
Isonitrogenous ornithine alpha-ketoglutarate versus
peptide supplements
Bean 1994, published only in abstract, investigated the effect of
oral ornithine alpha-ketoglutarate, compared to an isonitrogenous
peptide supplement, in 59 relatively undernourished older women
with hip fracture. Unfortunately, no denominators for the inten-
tion-to-treat analyseswere provided in the abstract, which reported
that recruitment was slow and that compliance with the supple-
ments for the full two months was poor. Bean 1994 reported
that there was no difference in mortality (ornithine alpha-ketog-
lutarate supplemented 12.5%, control 11.1%, no denominators
provided), compliance, duration of treatment or hospitalisation
between the two groups. Bean 1994 reported there was no sig-
nificant difference in complications but that major complications
were significantly delayed in the intervention group (reported P <
0.03). No information was given in the abstract about the effect of
the supplements on volitional food intake, although food diaries
were kept.
Dietetic assistants versus usual care
Duncan 2006 evaluated the use of dietetic assistants, who checked
food preferences, helped order meals and supplements, provided
feeding aids, assisted with food choice, and assisted with feeding
at meal times. Mortality at four months was lower in the inter-
vention group (see Analysis 7.1: RR 0.57, 99% CI 0.29 to 1.11)
but the difference between the two groups (P = 0.03) was not sta-
tistically significant by our criteria (P < 0.01). The incidence of
complications was similar in the two groups (see Analysis 7.2: RR
0.90, 99% CI 0.71 to 1.15). Duncan 2006 found no significant
differences between the two groups in the lengths of stay in the
acute ward (median 16 days versus 17 days; reported P = 0.44)
or in hospital (34 days versus 32 days; reported P = 0.81). Us-
ing their own scoring scheme, Duncan 2006 reported that patient
satisfaction was significantly greater in the intervention group at
discharge (reported P < 0.0001). The mean daily energy intake
was 349 kcal higher in the intervention group; this was mostly
from supplements.
D I S C U S S I O N
Summary of main results
This reviewhas identified only very limited evidence for the benefit
of nutritional supplementation after hip fracture. The variety of
interventions and outcomes made data synthesis difficult. The
failure to confirm an effect does not mean that there is no effect,
but may simply reflect poor study design and inadequate size.
Multinutrient supplementation
Oral supplements
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Oral supplementation has no proven effect on post hip fracture
mortality, but may possibly reduce ’unfavourable outcome’ (death
or complications). In previous versions of this review this outcome
was statistically significant, but attention was drawn to the poor
quality of the data. This is based on a very limited number of
studies, and Delmi 1990 did not account for all the participants
randomised. The effect of oral multinutrient supplementation on
length of stay in hospital (acute and rehabilitation) is unclear.
Administrative procedures, rather than the health of the patient
may particularly influence this outcome.
Nasogastric tube feeding
No clear effect of nasogastric feeding is evident. The suggestion
fromBastow 1983 that very thin patients may have reduced length
of hospital stay requires confirmation. The high mortality in the
intervention group in Hartgrink 1998 is unexplained, although
the study appears to have been well conducted. Tube feeding was
often poorly tolerated. One study of this group (Sullivan 1998) is
unusual in that most of the trial participants were male, whereas
most older people with hip fracture are female.
Nasogastric tube feeding and oral supplements
Tube feeding followed by oral supplementation has no proven
effect onmortality or complications. Sullivan 2004, in whichmost
trial participants were male, found that tube feeding was poorly
tolerated.
Intravenous feeding and oral supplements
Eneroth 2006 found that a combination of intravenous feeding
and oral supplements may reduce complications. However, intra-
venous feeding is an expensive, technically complex intervention
which is usually reserved for people with non-functioning gas-
trointestinal tracts, which is unlikely in this group.
Nutritional status
There is no clear evidence to confirm that malnourished partici-
pants are more likely to benefit from multinutrient supplementa-
tion than those participants who are not malnourished.
Increasing protein intake
A higher intake of protein may reduce the length of time spent
in a rehabilitation hospital and numbers of complications, but
has no proven effect on mortality. The studies are flawed by their
failure to account for all participants. The results for mortality and
’unfavourable outcome’ for Espaulella 2000 are contradictory and
while many reasons for this, including that of random variation,
can be put forward, none can be confirmed. There is weak evidence
that including protein in the supplement improves rehabilitation.
Other supplements
No evidence can be found from the two studies of Day 1988 and
Hoikka 1980 to recommend the supplementation of vitamin B1
and other water soluble vitamins, or 1-alpha-hydroxycholecalcif-
erol. Ornithine alpha-ketoglutarate, compared with an isonitroge-
nous peptide supplement, may delay the onset of complications
post hip-fracture, but this is based on very weak evidence from one
unpublished study (Bean 1994) and no significant difference in
the incidence of complications was reported. No trials examined
the effect of specific amino acid formulations.
Dietetic assistants
The use of dietetic assistants was associated with lower trauma
unit mortality in one trial. However, the difference between the
two groups was not statistically significant by our criteria (99%
confidence intervals for results from single trials). There were no
statistically significant differences in the number of complications
nor length of hospital stay. Duncan 2006 reported increased con-
sumption of supplements and greater patient satisfaction in the
intervention group. These favourable results (especially in terms
of mortality) need to be checked in further randomised controlled
trials.
Overall completeness and applicability of
evidence
Given that people with hip fracture are often malnourished, it is
notable that this review gives no clear evidence that those who are
malnourished are more likely to benefit from multinutrient sup-
plementation than those who are not malnourished. The lack of a
statistically significant difference in results of trials may be due not
only to the small sample sizes, but also to the different definitions
of malnutrition in individual trials. Quite possibly, people who
are malnourished benefit more from nutritional supplementation,
especially if they are severely malnourished, but more evidence is
needed.
Incomplete compliance with nutritional supplementation was a
major problem in these studies. Inability to tolerate nasogastric
tubes and problems with palatability of oral feeds are common,
particularly in confused, frail people. Malnutrition in itself pro-
duces mental apathy (Keys 1950), which may further reduce sup-
plement intake. Ensuring increased nutritional intake thus has a
major implication for nursing care, and has ethical implications
when a person appears unwilling to feed or tolerate nasogastric
feeding. While the combined intervention of nutritional supple-
mentation and exercises tested in Miller 2006 was excluded from
this review, the potential interaction between these two interven-
tions merits further investigation.
Nasogastric feeding, if tolerated, allows the provision of higher
supplements of energy (3.90 to 6.28 MJ, or 933 kcal to 1500 kcal
daily, in the studies in this review), whereas oral supplements in
the studies reviewed here generally provided under 2.51 MJ (600
kcal) daily. Thus nasogastric feeding, which potentially has more
risk of complications, is likely to be targeted at those requiring
higher levels of supplementation. Attempts to overcome the poor
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palatability of oral supplements, and thus increase intakes further,
include special high energy hospital meals and the provision of
frequent, small snacks (Gall 1998). Related to this are other mea-
sures taken to encourage consumption of food by patients. For ex-
ample, one of the excluded studies examined the effects of actively
involving patients in their own dietary care, a procedure based on
Salling’s nursing model involving a dietary journal, information,
guidance and instruction (Pedersen 1999). Dietetic assistants may
be another way to increase food and supplement intake, as in the
study by Duncan 2006, which requires examination in further re-
search, including an economic evaluation.
Intravenous feeding used in Eneroth 2006 provided an additional
1000 kcal and 53 g protein daily, thus also allowing higher levels
of supplementation. However, it also carries risks of fluid and elec-
trolyte imbalance, hyperglycaemia and thrombophlebitiswhende-
livered through a peripheral vein.
Nutritional supplementation should also be viewed in the con-
text of general nutrition in hospitals. Given the high numbers of
hip fracture patients with prior malnutrition, and the prolonged
length of stay, it is surprising that nutrition, including the provi-
sion and uptake of basic foodstuffs, is often understated, or even
overlooked, as a component of rehabilitative care programmes.
Indeed, earlier guidelines for hip fracture management provided
by the Scottish Intercollegiate Guidelines Network (SIGN 1997)
failed to consider nutrition in rehabilitation; however, this omis-
sion was remedied subsequently (SIGN 2002).
There is interest in the hypothesis that nutritional supplementa-
tion may attenuate bone loss after fracture, which may also help
to decrease the risk of further fractures (Schürch 1998a).
Quality of the evidence
The studies are limited by inadequate sample size, failure to un-
dertake intention-to-treat analysis (with frequent exclusion of par-
ticipants for failing to take the supplements), failure to blind out-
come assessors, failure to report and categorise participants’ nutri-
tional status, and inadequate period of follow-up with insufficient
ascertainment of important outcomes.
Potential biases in the review process
We think that it is unlikely that the review process itself has intro-
duced bias. Our search, updated fully on a regular basis, is com-
prehensive and we actively pursue unpublished trials and data as
well as ongoing and newly registered trials. We have used robust
methodology, including independent trial selection and review of
included trials, for the throughout the review and updating pro-
cesses. Although we have not adopted risk of bias tables for this
update, we have enhanced our methods in other ways including
additional transparency for results not shown in the analyses.
Agreements and disagreements with other
studies or reviews
One review author (AA) has contributed to two more general sys-
tematic reviews of protein and energy supplementation in older
people at risk from malnutrition (Milne 2006; Milne 2009). The
above described limitations in the studies of this review also apply
to nutritional intervention trials for other patient groups. Milne
2009 found that while there was no significant reduction in mor-
tality in the supplemented compared with control groups overall,
mortality results were statistically significant when limited to trials
in which participants (N = 2461) were defined as undernourished.
They concluded that there was a beneficial effect on complica-
tions but considered this needs confirmation. Despite the shared
problem of malnutrition, the applicability of results from a more
general population to people with hip fracture is still questionable
and we consider that the focus of future research should remain
on this particular patient group.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The strongest evidence of the effectiveness of nutritional supple-
mentation exists for oral or oral and intravenous multinutrient
feeds, but the evidence is still very weak. The benefits of naso-
gastric feeding are even less certain, and it should probably be
reserved for the very malnourished, with extremely poor intakes
not responsive to oral supplementation. Although tested in just
one trial and needing confirmation, there is also weak evidence in
favour of dietetic assistants.
Implications for research
• Large, well-designed, adequately powered, trials of oral
multinutrient supplementation, either by sip feeds and/or the
hospital diet, are required, which should seek to be as inclusive of
the patient population as possible. The provision of extra staff to
help with feeding, e.g. dietetic assistants, should be explored
further. Such trials should stratify allocation according to basic
nutritional status to enable robust a priori subgroup analysis.
• Large, well-designed, adequately powered, trials of
nasogastric or intravenous multinutrient supplementation should
be conducted only in the most malnourished patients, where oral
supplementation is unable to provide sufficient intake.
• The design and reporting of any future trial should
conform to the CONSORT statement (Begg 1996; Moher
2001) or any future development of it.
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• Future research should examine functional status (using
standardised methods), the level of care required, compliance,
patient perceived quality of life, and direct and indirect costs
after hip fracture. These are in addition to mortality, individual
complications and length of stay in hospital and rehabilitation.
An independent observer should assess outcomes and the period
of follow up should be at least one year.
Information on nutritional status and use of supplements should
be collected in audits of hip fracture management. Such data could
be used to investigate the relationship of nutritional status to out-
come.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bastow 1983
Methods Method of randomisation: quasi-randomised
Assessor blinding: unlikely
Intention-to-treat analysis: appears so
Lost to follow-up: appears none
Participants Location: hospital, Nottingham, UK
Period of study: over 18 months, probably prior to 1983
122 participants
Inclusion criteria: hip fracture, mid-arm circumference or triceps skinfold, or both, one to two standard
deviations below themean (thin group) or over two standard deviations below themean (very thin group)
Exclusion criteria: incapable of understanding study, severe dementia, serious concomitant physical dis-
order e.g. stroke
Sex: all female
Age: range 68-92 years
Fracture type: further details not given
Interventions Timing of intervention: nasogastric feeding started within 5 days of surgery, 8 hours overnight with tube
disconnected during the day, until discharge or death. Feeding stopped if participant did not tolerate tube
or removed tube on 3 occasions
(a) 1 L Clinifeed Iso (4.2 MJ or 1000 kcal, 28 g protein, 270 mosmol/L) via fine bore nasogastric tube
using peristaltic pump, and normal ward diet, with free access to snacks and drinks
(b) Normal ward diet, with free access to snacks and drinks
Allocated: 64/58
Assessed: 60/49 for independent mobility
Outcomes Length of follow-up: until discharge or death
Main outcomes:
Mortality
Morbidity and complications: infection
Length of stay: hospital stay
Postoperative functional status: days to weight bearing with support, days to independent mobility
Putative side effects of treatment: aspiration, diarrhoea
Other outcomes:
Anthropometric indices: weight, triceps skinfold, mid-arm circumference
Nutritional indicators measured in blood: haemoglobin (*nr), albumin, thyroid binding prealbumin
Other nutritional: voluntary food intake
Patient compliance: tolerance of tube, duration of feeding
Notes There was an administrative limit imposed of a maximum of 6 patients being fed at one time. Data
presented from 1983 paper for numbers of participants are correct, error in number of participants in
1985 paper. Slight discrepancy with days to reach independent mobility presented in 1984 abstract. Reply
from trialist (15/2/00) gave details of randomisation (on recall: either by date of admission or birth),
outcome assessment, inclusion criteria, denominators and baseline comparability
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Bastow 1983 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Quasi-randomised. On recall by trialist: “either on
the basis of odd and even dates of birth or of admis-
sion”.
Bean 1994
Methods Method of randomisation: states double-blind, but no details
Assessor blinding: not reported
Intention-to-treat analysis: claimed by authors, but no details to support
Lost to follow-up: details not given
Participants Location: hospitals; Nottingham, Leeds and Doncaster, UK
Period of study: recruitment over 2.5 years
59 participants
Inclusion criteria: fractured femur, 70-85 years, mean arm circumference < 25 cm, triceps skinfold < 18
mm
Exclusion criteria: other major medical disorder, failure to gain consent, demented (Cape score less than
9/12)
Sex: all female
Age: not given
Fracture type: further details not given
Interventions Timing of interventions: start time unclear, twice daily for 2 months,
(a) Cetornan (ornithine a-ketoglutarate)20 g/d (0.293 MJ or 70 kcal, 2.73 g N), presumed orally
(b) Pro-up (defined formula peptide supplement, 0.293 MJ or 70 kcal, 2.73 g N), presumed orally
Allocated: ?/?
Assessed: ?/?
Outcomes Length of follow-up: 6 months
Main outcomes:
Mortality
Morbidity and complications: all complications and delay in major complications (*nr)
Length of stay: duration of treatment or hospitalisation (*nr)
Postoperative functional status: fatigue score (*nr)
Other outcomes:
Anthropometric indices: arm muscle circumference (*nr)
Other nutritional: food intake (*nr)
Patient compliance: proportion completing 2 months’ treatment (*nr)
Notes Conference abstract only. No denominators for intention-to-treat analysis, so cannot use data in analysis.
Data on armmuscle circumference, fatigue score and food intake presented for 35 participants completing
2 months of treatment. Request for further details (including denominators)sent 19/5/99, resent 4/2/00
Risk of bias
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Bean 1994 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear “randomized in a double-blind fashion”
Botella-Carretero 2008
Methods Method of randomisation: sealed opaque envelopes, prepared independently from recruitment
Assessor blinding: not done
Intention-to-treat analysis: unclear
Lost to follow-up: details given
Participants Location: Hospital Ramon y Cajal, Madrid, Spain
Period of study: February 2006 to February 2007
90 participants
Inclusion criteria: > 65 years, surgery for hip fracture, written informed consent.
Exclusion criteria: weight loss > 5% in previous month or > 10% in previous 6 months, and/or albumin
< 27 g/dL. Acute or chronic renal failure, hepatic insufficiency or cirrhosis (Child B or C), severe heart
failure (New York heart classification III or IV), respiratory failure, gastrointestinal condition precluding
adequate oral intake. Also: previous oral nutrition supplements or nutrition support in previous 6months.
Sex: 71 female, 19 male
Age: mean age 84 years
Fracture type: not given
Interventions Timing of intervention: started 48 hours after operation, until hospital discharge
(a) Four 10 g packets a day of Vegenat-med Proteina (Vegenat SA, Badajoz, Spain) each providing 9 g
protein and 38 kcal, dissolved in water, milk or soup from diet.
(b) Two 200 ml bricks a day (Resource Hiperproteico, Novartis Medical Nutrition, Barcelona)providing
total of 37.6 g protein and 500 kcal.
(c) no oral nutrition supplements.
Allocated: 30/30/30
Assessed: 28/30/27
Outcomes Length of follow-up: up to hospital discharge
Main outcomes:
Mortality
Complications: urinary, respiratory, wound infection; pressure ulcer, dysphagia, ischaemic heart disease;
severe hyponatraemia; anaphylaxis; vomiting and/or diarrhoea
Length of acute hospital stay
Level of care: time to mobilisation
Other outcomes:
Other nutritional: energy and protein intake
Notes Emailed 22nd January 2009 requesting mortality information. Author replied 23rd January confirming
no participants had died during the trial.
Risk of bias
Item Authors’ judgement Description
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Botella-Carretero 2008 (Continued)
Allocation concealment? Yes Use of “sealed opaque envelopes”. Independent
preparation of envelopes: “The investigator recruit-
ing the patients ....had no role in the randomisation
process”.
Brown 1992
Methods Method of randomisation: alternating numbers
Assessor blinding: blinded
Intention-to-treat analysis: carried out
Lost to follow-up: no losses to follow-up
Participants Location: hospital, Ipswich, UK
Period of study: six months, probably prior to 1992
10 participants
Inclusion criteria: thin (based on weight for height, triceps skinfold, mid-arm circumference - two out of
three more than one standard deviation below reference mean), elderly, females with hip fracture
Exclusion criteria: malignant disease, mental illness, renal or hepatic failure, neurological disorder, stroke,
diabetes
Sex: all female
Age: not given, but “elderly”
Fracture type: trochanteric or subcapital hip fracture
Interventions Timing of intervention: from second day of admission until discharge (including rehabilitation hospital)
(a) Participant offered oral nutritional supplement Fresubin (Fresenius)calculated to make up deficit
between intake from normal hospital diet and requirement. Fresubin provides 4.2 kJ or 1 kcal/ml, as 15%
protein energy, 30% fat energy and 55% carbohydrate energy
(b) Normal hospital diet
Allocated: 5/5
Assessed: 5/5
Outcomes Length of follow-up: no details (21+ days)
Main outcomes:
Mortality
Morbidity and complications: pressure sore (*nr)
Length of stay: days to discharge from orthopaedic surgeon
Postoperative functional status: two stage walking goals
Other outcomes:
Anthropometric indices: percentage losses in weight, triceps skinfold, midarm circumference, arm muscle
circumference
Nutritional indicators measured in blood: albumin, prealbumin, zinc, magnesium (all *nr)
Other nutritional: dietary intake (*nr)
Notes Author provided protocol of trial and information on method of randomisation and outcome assessment.
Request for further details (other outcomes, period of follow-up)sent 19/5/99, resent 3/2/00
Risk of bias
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Brown 1992 (Continued)
Item Authors’ judgement Description
Allocation concealment? No Alternating numbers (information from trial au-
thor).
Bruce 2003
Methods Method of randomisation: quasi-randomised by year of birth
Assessor blinding: not reported
Intention-to-treat analysis: unclear (though likely)
Lost to follow-up: no withdrawals but some unaccounted “missing data points”
Participants Location: hospital, Freemantle, Australia
Period of study: patients admitted June 1998 to December 1999
109 participants
Inclusion criteria: women with hip fracture, consent given
Exclusion criteria: BMI <20 or >30 kg/m2, nursing home resident, resident outside metropolitan Perth (
preventing follow up), diseases expected to influence nutritional intake (malignancy, severe organ failure),
diabetes (to avoid potential hyperglycaemia), fracture due to major trauma
Sex: 109 female
Age: mean 84 years
Fracture type: further details not given
Interventions Timing of intervention: started within 2 to 3 days after surgery, for 28 days
(a) One 235ml can of Sustagen Plus daily (Mead Johnston), providing 352 kcal or 1.47MJ, 17.6 g protein,
11.8 g fat, 44.2 g carbohydrate, 376 mcg retinol equivalents, 1.2 mcg vitamin D, 2.4 mg vitamin E, 15
mg vitamin C, 0.4 mg thiamin, 0.5 mg riboflavin, 8.7 mg niacin, 0.6 mg vitamin B6, 0.9 mcg vitamin
B12, 71 mcg folate, 1.9 mg pantothenic acid, 14 mcg biotin, 259 mg sodium, 491 mg potassium, 371 mg
chloride, 263 mg calcium, 261 mg phosphorus, 3.8 mg iron, 106 mg magnesium, 3.8 mg zinc, 41 mcg
iodine, 0.4 mg copper, 0.6 mg manganese, 19 mcg selenium, 19 mcg chromium, 47 mcg molybdenum;
chocolate and vanilla flavours. Dietitian carried out preliminary taste test and offered encouragement and
strategies to help with compliance, e.g. ways to alter taste and timing of supplement. And routine care
(b) Routine care
Allocated: 50/59
Assessed: ?/?
Outcomes Length of follow-up: 6 months
Main outcomes:
Mortality: combined outcome with need for nursing home
Length of stay: hospital
Postoperative functional status: % with fall in Katz score
Level of care and extent of support required after discharge: % discharged home, % home at 6 months
Other outcomes:
Anthropometric indices: weight
Nutritional indicators in blood: albumin
Patient compliance: consumption of cans of supplement
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Bruce 2003 (Continued)
Notes Percentages provided in report indicate variation in denominators used. Requests for further details of
denominators and deaths during study sent 13/8/03 and 13/10/03. Reply received October 2003 giving
details of denominators, deaths, withdrawals, and details of vitamin and mineral content of supplement
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No “Quasi-randomisation of cases was carried out using
their date of birth.”
Day 1988
Methods Method of randomisation: computer-generated random sequence, insufficient indication of adequate
safeguards
Assessor blinding: blinded assessment of mental state, other outcomes not stated
Intention-to-treat analysis: analysis performed
Lost to follow-up: details given
Participants Location: hospital, Cardiff, UK
Period of study: recruitment over six months, probably prior to 1988
60 participants
Inclusion criteria: people with acute proximal femur fracture, age 60+years
Exclusion criteria: unable to be assessed preoperatively, not seenwithin 24 hours of admission, pathological
fracture, difficulty obtaining consent from patient or relative
Sex: 44 female, 16 male
Age: 60 years and older (inclusion criterion)
Fracture type: 17 cervical, 9 trochanteric, 2 other/16 cervical, 14 trochanteric, 2 other
Interventions Timing of intervention: Two doses of vitamin preparation given preoperatively, and then one dose daily
for five postoperative days
(a) Intravenous Parentrovite IVHP (containing 250 mg thiamine hydrochloride, 4 mg riboflavine, 50 mg
pyridoxine, 160 mg nicotinamide, 500 mg ascorbic acid, 1 g anhydrous dextrose)
(b) No supplement
Allocated: 28/32
Assessed: 28/32 for abbreviated mental test at day 2
Outcomes Length of follow-up: 3 months
Main outcomes:
Mortality
Morbidity and complications: total number of complications, numbers of participants with complications
Length of stay: hospital
Postoperative functional status: acute confusional state, acute on chronic confusional state, abbreviated
mental test, objective learning test, Ishihara Colour Plates
Care required after discharge: final placement
Putative side effects of treatment: serious and other adverse events
Other outcomes:
Nutritional indicators measured in blood: thiamine status by thiamine pyrophosphate activation of red
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Day 1988 (Continued)
cell transketolase
Notes Request for further details (method of randomisation, constituents of Parentrovite IVHP, other outcomes)
sent. Reply from trialist (27/5/99) gave details of the intervention, and information on fracture type,
baseline albumin levels, complications and hospital stay
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear “Allocation of patients was based on randomly gen-
erated numbers”. However, no indication of ade-
quate safeguards for allocation concealment.
Delmi 1990
Methods Method of randomisation: not stated
Assessor blinding: not reported
Intention-to-treat analysis: appears intention to treat, but denominators unclear
Lost to follow-up: deaths reported, but unclear if other losses to follow-up
Participants Location: orthopaedic unit in hospital and recovery hospital, Geneva, Switzerland
Period of study: 1 March to 15 May 1985
59 participants
Inclusion criteria: femoral neck fracture after an accidental fall, aged over 60 years
Exclusion criteria: fracture from violent external trauma, pathological fracture due to tumour or non-
osteoporotic osteopathy; overt dementia; renal, hepatic, or endocrine disease; gastrectomy or malabsorp-
tion; taking phenytoin, steroids, barbiturates, fluoride or calcitonin
Sex: 53 female, 6 male
Age: mean age 82 years
Fracture type: 26 femoral neck, 33 inter-trochanteric
Interventions Timing of intervention: from admission to orthopaedic unit to end of stay in second (recovery) hospital,
supplement given once daily at 20.00 hours for a mean period of 32 days.
(a) 250 ml oral nutritional supplement (1.06 MJ or 254 kcal, 20.4 g protein, 29.5 g carbohydrate, 5.8 g
lipid, 525 mg calcium, 750 IU vitamin A, 25 IU vitamin D3, nicotinamide, folate, calcium pantothenate,
biotin, minerals; and vitamins E, B1, B2, B6, B12, C) and standard hospital diet
(b) Standard hospital diet
Allocated: 27/32
Assessed: ?25/?27 at 6 months
Outcomes Length of follow-up: 6 months
Main outcomes:
Mortality
Morbidity and complications: complications (total, bedsore, severe anaemia, cardiac failure, infection,
gastrointestinal ulcer, other), favourable clinical course (excludes death, major complication, or two or
more minor complications)
Length of stay: orthopaedic unit and recovery hospital
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Delmi 1990 (Continued)
Other outcomes:
Nutritional indicators measured in blood: albumin, transferrin (*nr)
Other nutritional: energy, protein and calcium intake
Notes Numbers of complications unclear, request for further details sent 24/5/99, resent 7/2/00
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear No information. Just “randomised”.
Duncan 2006
Methods Method of randomisation: sequentially numbered opaque sealed envelopes, initially in blocks of 20, later
reduced to blocks of 10, prepared by member of staff outside trial, opened sequentially
Assessor blinding: appears so
Intention-to-treat analysis: post-randomisation exclusion of people for conservative care of hip fracture
Lost to follow-up: details given
Participants Location: single trauma ward, University Hospital of Wales, Cardiff, UK
Period of study: recruitment May 2000 to August 2003
318 participants
Inclusion criteria: women aged over 65 years presenting to trauma ward with acute nonpathological hip
fracture, consent or assent to trial
Exclusion criteria: none
Sex: all female
Age: mean age 84 years
Fracture type: not given
Interventions Timing of intervention: unclear when commenced, during stay in acute trauma ward, median 16-17 days.
Dietetic assistant present on ward 6 hours/day for 7 days a week
(a) additional attention of dietetic assistant (previous NHS experience, given 14 day period of orientation
and training), working closely with specialist dietitian. Asked to ensure participants met nutritional needs,
including by: checking personal and cultural food preferences; co-ordinating appropriate meal orders with
catering staff; ordering nutritional supplements; provision of feeding aids; assisting with food choice,
portion size and positioning at mealtimes; sitting with, encouraging and feeding; collecting information
to aid nutritional assessment by dietitian
(b) Nurse and dietitian led care, including routine provision of oral nutritional supplements to all partic-
ipants
Allocated: 153/165
Assessed: 145/157 for mortality
Outcomes Length of follow-up: 4 months
Main outcomes:
Mortality
Morbidity and complications: on trauma ward in survivors
Length of trauma ward and hospital stay
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Duncan 2006 (Continued)
Other outcomes:
Changes in anthropometric indices: weight, mid-arm circumference, triceps skinfold
Changes in nutritional indicators measured in blood: albumin, lymphocyte count
Functional markers of nutritional status: hand grip strength
Other nutritional: energy intake
Notes Request for further details on participants with complications sent 15/3/06. Reply from trialist (15/3/06)
provided number and per cent of live participants having had complications on trauma ward.
A letter to the editor in Age and Ageing Advance Access (June 24, 2006) by Hewitt and Torgerson pointed
out the numerical difference between the two groups was higher than expected given the reported block
size of 10. The reply from Duncan indicated that they initially started the study with a block size of 20.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes “Randomisation was by sequentially numbered,
opaque, sealed envelope method in blocks of 10,
prepared by a member of staff not directly involved
in the trial.”
Eneroth 2006
Methods Method of randomisation: block randomisation conducted by research nurse, using closed, numbered
envelopes
Assessor blinding: no
Intention-to-treat analysis: appears so
Lost to follow-up: details given
Participants Location: department of orthopaedics, Lund University Hospital, Lund, Sweden
Period of study: before August 2005
80 participants
Inclusion criteria: over 60 years with a cervical or trochanteric hip fracture, written informed consent,
surgery < 48 hours from trauma.
Exclusion criteria: multiple fractures, pathological fractures, malignancy, inflammatory joint disease, pain
or functional impairment other than hip fracture whichmight hampermobilization, dementia, depression,
acute psychosis, known alcohol ormedication abuse, epilepsy,mini-mental test score < 6, warfarin, insulin-
treated diabetes; heart, kidney ore liver insufficiency, suspected acutemyocardial infarction, haematemesis.
Sex: 63 female, 17 male
Age: mean age 81 years
Fracture type: 45 cervical, 35 trochanteric
Interventions Timing of intervention: first 10 days in hospital
(a) 1000 ml Vitrimix (Kabi Pharmacia AB, Sweden) intravenously (amino acids, fat, carbohydrate, elec-
trolytes daily for 3 days (100 kcal, 53 g protein daily), then 7 days oral Fortimel 400 ml (400 kcal.day;
Nutricia AB, Netherlands). Trace elements (Tracel, Kabi Pharmacia AB), water and fat soluble vitamins
(Soluvit Novum and Vitalipid Novum, Kabi Pharmacia AB) were added to Vitrimix.
(b) Usual hospital diet.
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Eneroth 2006 (Continued)
Allocated: 40/40
Assessed: 40/40 for mortality
Outcomes Length of follow-up: mean of 120 days
Main outcomes:
Mortality
Complications: wound infection, pneumonia, urinary infections, thrombophlebitis, deep vein thrombosis,
pulmonary embolism, pulmonary oedema, myocardial infarction
Length of acute hospital stay
Level of care: discharge to own home
Other outcomes:
Other nutritional: energy intake, fluid intake
Notes Emailed on 22nd January 2009 in an attempt to clarify denominators. Author replied 10th February
confirming denominators.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear “A research nurse (UBO) randomized 80 patients
to either a control or an intervention group using
block randomization with 40 closed and numbered
envelopes in each block.”
Espaulella 2000
Methods Method of randomisation: computer generated assignment, balanced in blocks of four, with sealed en-
velopes, opened by pharmacist
Assessor blinding: blinded
Intention-to-treat analysis: 10 excluded: 8 excluded for protocol violation and 2 excluded because they
could not swallow - intention-to-treat analysis not possible
Lost to follow-up: details given
Participants Location: Hospital General de Vic, Barcelona
Period of study: July 1994 to July 1996
171 participants
Inclusion criteria: hospitalised for fracture of the proximal femur, aged 70 years and over
Exclusion criteria: advanced dementia, needing intravenous nutrition, pathological fracture, fracture not
due to accidental fall
Sex: 135 female, 36 male
Age: mean 82.6 years
Fracture type: 115 extracapsular, 56 intracapsular hip fractures
Interventions Timing of intervention: begun within 48 hours of study entry, consumed once daily at night for 60 days
(a) 200 ml oral supplement in 3 flavours (0.62 MJ or 149 kcal, 20 g protein, 1.5 g carbohydrate, 7 g
fat, 800 mg calcium, 3 IU vitamin A, 1.7 mg thiamin, 2.02 mg riboflavin, 2.25 mg pyridioxine, 5.5 mcg
vitamin B12, 122.25 mg vitamin C, 25 IU vitamin D3, 10 mg calcium pantothenate, 16.87 mg vitamin
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Espaulella 2000 (Continued)
E, 0.45 mg biotin, 500 mcg folic acid, 22.5 mg nicotinamide), prepared by pharmaceutical company
(Clinical Nutrition S.A., Spain)
(b) 200 ml oral supplement in 3 flavours (0.65 MJ or 155 kcal as 25.3 g carbohydrate and 6 g fat),
prepared by pharmaceutical company
Allocated: 85/86
Assessed: 61/67 for all outcomes
Outcomes Length of follow-up: 6 months
Main outcomes:
Mortality: all cause and related to fracture, days between fracture and death (survival curve)
Morbidity and complications: including delirium, bed sore, urinary tract infection
Length of stay: acute hospital ward
Postoperative functional status: Barthel Index, Mobility Index, days from surgery to walking
Level of care and extent of support required after discharge: discharge home or geriatric rehabilitation
unit, use of walking aids at 6 months
Other outcomes:
Nutritional indicators measured in blood: albumin
Patient compliance
Notes Request for further details (including follow-up data on excluded participants, details of supplement)
sent 14/2/00 and 6/6/00. Replies from Guyer (6/3/00 and 13/6/00) confirmed assessor blinding, gave
other details of methodology and contents of supplement, as well as details of outcome of the excluded
participants.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Computer generated assignment, balanced in blocks
of four, with sealed envelopes, prepared by epidemi-
ology unit. “Upon being advised of a patient’s in-
clusion, the pharmacist assigned the patient a study
number and opened the envelope ...”
Gallagher 1992
Methods Method of randomisation: not stated
Assessor blinding: not reported
Intention-to-treat analysis: not reported
Lost to follow-up: not reported
Participants Location: hospital, Cincinnati, USA
Period of study: over 15 months
97 participants
Inclusion criteria: people with hip fracture having surgery, serum albumin < 3.5 g/dL on admission
Exclusion criteria: no details
Sex: male and female, numbers not given
Age: not given
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Gallagher 1992 (Continued)
Fracture type: not given
Interventions Timing of intervention: tube placed in surgery, supplementary feeding began first post-operative night,
11 hours per night, continued until participant ate 75% of their calorie needs for 3 consecutive days
(a) Small-bore nasogastric tube providing 3.90 MJ or 933 kcal, 33 g protein each night; normal diet and
snacks
(b) Normal diet and snacks
Allocated: ?/?
Assessed: ?/?
Outcomes Length of follow-up: no details (21+ days)
Main outcomes:
Morbidity and complications: surgical and gastrointestinal
Length of stay: rehabilitation stay
Postoperative functional status: days to meet physical therapy goals
Other outcomes:
Nutritional indicators measured in blood: albumin and transferrin
Notes Conference abstract with no denominators, so cannot use data in analysis. Notes taken by Ronald Koretz
of an oral conference presentation by Gallagher indicated a quasi-randomised study with dropouts being
placed in control group; thus denominators remain unclear. The notes gave details of total length of stay,
numbers pulling out nasogastric tube, deaths, and medical and surgical complications.
Request for further details (including denominators)sent 26/2/99, resent 3/2/00
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear No information: “randomized”.
Hankins 1996
Methods Method of randomisation: sealed, opaque envelopes in blocks of 10, appears stratified by place of residence
Assessor blinding: not done
Intention-to-treat analysis: carried out
Lost to follow-up: details given
Participants Location: acute care in Hornsby-Kuringai Hospital and rehabilitation hospitals, Sydney, Australia
Period of study: admissions from 16 May to 8 August 1996
32 participants
Inclusion criteria: fractured neck of femur after accidental fall; admitted from home, hostel or nursing
home; age 65 years or older; mid-upper arm circumference less than or equal to 25th centile for sex and
age
Exclusion criteria: malignancy, chronic renal failure, hepatic disease, no consent from patient or next of
kin, did not reside locally, not notified of admission, unstable diabetes
Sex: 27 female, 5 male
Age: mean 86 years
Fracture type: not given
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Interventions Timing of intervention: started within 5 days of surgery, given once in the morning and once in the
evening for 30 days, served on meal tray in hospital by nurses, given by family or self-administered out of
hospital
(a) Oral supplement of 250 ml Sustagen twice daily (total daily intake 22.5 g protein, 10 g fat, 60 g
carbohydrate, 1.712 MJ or 409 kcal energy, 500 mcg vitamin A, 6.6 mcg vitamin D, 50.8 mg vitamin
C, 1.2 mg thiamin, 1.15 mg riboflavin, 13 mg niacin, 1.3 mcg vitamin B12, 825 mg calcium, 670 mg
phosphorus, 8 mg iron, 66 mcg iodine, 1.2 g potassium, 370 mg sodium) plus standard hospital diet
(b) Standard hospital diet
Allocated: 17/15
Assessed: 17/14
Outcomes Length of follow-up: 2 months
Main outcomes:
Mortality
Morbidity and complications: complications (total, infection, pressure sores, pulmonary embolism, delir-
ium, anaemia, cardiac failure, acute renal failure), favourable clinical course (excludes death, major com-
plication, or two or more minor complications)
Length of stay:acute hospital, rehabilitation hospital, and total stay
Postoperative functional status: Barthel Index
Care required after discharge: place of residence at two months
Other outcomes:
Anthropometric indices: self-reported weight, mid-upper arm circumference
Other nutritional: energy, protein intakes from food and supplement; calcium, iron and vitamin C intakes
from food
Patient compliance: numbers completing full 30 days of supplement
Notes Request for further details (blinding of outcome assessors, details of supplement administration, further
information on outcomes) sent. Reply from trialist (11/6/99) gave details of outcome assessor blinding,
supplement administration and outcomes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes “Sealed, numbered opaque envelopes in blocks of
10”. Information from Ian Cameron
Hartgrink 1998
Methods Method of randomisation: computer generated randomisation list. Use of numbered envelopes.
Assessor blinding: no, but statistician appeared blinded
Intention-to-treat analysis: attempted, but 11 randomised participants subsequently excluded for not
fulfilling entry criteria
Lost to follow-up: details given
Participants Location: teaching hospital, The Hague, The Netherlands
Period of study: May 1993 to November 1995
140 participants
41Nutritional supplementation for hip fracture aftercare in older people (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hartgrink 1998 (Continued)
Inclusion criteria: hip fracture, pressure sore risk score of 8 or above (out of a possible 30), gave consent
Exclusion criteria: pressure sores of grade 2 (blister formation)or more at admission
Sex: 122 female, 18 male
Age: mean 83.6 years
Fracture type (of 129): 60 medial, 15 lateral, 53 trochanteric, 1 other hip fracture
Interventions Timing of intervention: nasogastric tube placed during surgery or within 12 hours afterwards. Feeding
started within 24 hours of surgery. Intended duration of feeding 2 weeks. Feed administered between
21.00 hours and 05.00 hours to minimise interference with standard hospital diet.
(a) Nasogastric tube feed of 1 L Nutrison Steriflo Energy-plus ( 340 mosmol/L, 6.28 MJ or 1500 kcal,
60 g protein, 184 g carbohydrate, 58 g fat, 800 mg sodium, 1350 mg potassium, 1250 mg chloride, 570
mg calcium, 570 mg phosphate, 200 mg magnesium, 10 mg iron, 10 mg zinc, 1.5 mg copper, 3 mg
manganese, 1 mg fluoride, 50 mcg molybdenum, 43 mcg selenium, 33 mcg chromium, 0.1 mg iodide,
670 mcg retinol equivalents, 5 mcg vitamin D, 8.1mg alpha tocopherol, 40 mcg vitamin K, 1mg thiamin,
1.1 mg riboflavin, 26 mg niacin, 4 mg pantothenic acid, 1.3 mg vitamin B6, 130 mcg folic acid, 2 mcg
vitamin B12, 100 mcg biotin, 50 mg vitamin C, 200 mg choline) plus normal hospital diet. If participant
removed tube, replaced a maximum of 3 times.
(b) Standard hospital diet
Allocated: 70/70
Assessed: 48/53
Outcomes Length of follow-up: 2 weeks
Main outcomes:
Mortality
Morbidity and complications:clinically relevant pressure sore
Length of stay: numbers discharged at 1 and 2 weeks
Putative side effects of treatment: aspiration pneumonia
Other outcomes:
Nutritional indicators measured in blood: haemoglobin, albumin
Other nutritional: energy and protein intakePatient compliance: compliance with tube feeding
Notes Request for further details (including supplement details and administration, randomisation process,
blinding of outcome assessors, details of 11 post-randomised participants excluded, other outcomes) sent.
Reply from trialist (23/6/99) gave baseline details on all participants randomised, method of randomisa-
tion, assessor blinding, supplement details and administration.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear “Randomisation list prior to trial was made by com-
puter”. “If informed consent a numbered envelope
was opened”. No information on adequate safe-
guards.
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Hoikka 1980
Methods Method of randomisation: quasi-randomised by date of birth
Assessor blinding: not reported
Intention-to-treat analysis: not reported
Lost to follow-up: not reported, but incomplete outcome ascertainment
Participants Location: hospital, Kuopio, Finland
Period of study: probably prior to 1980
37 participants
Inclusion criteria: hip fracture caused by moderate or no trauma
Exclusion criteria: under 50 years, renal disease, poor co-operation, clinically evident osteomalacia
Sex: 29 female, 8 male
Age: mean 74 years, range 55 to 86 years
Fracture type: further details not given
Interventions Timing of intervention: start time unclear, four months treatment.
(a) 1 mcg 1-alpha-hydroxycholecalciferol and 1 g calcium as calcium carbonate daily
(b) Placebo and 1 g calcium as calcium carbonate daily
Allocated: 19/18
Assessed: 13/15 at six months for muscle strength
Outcomes Length of follow up: 6 months
Main outcomes:
Putative side effects of treatment: hypercalcaemia
Other outcomes:
Bone mineral density
Functional markers of nutritional status: hand muscle strength
Notes Request for further details (timing of intervention, denominators for some outcomes) sent 11/5/99,
returned to sender. Details on method of randomisation received from Jane Robertson on 02/02/1999.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No Quasi-randomised by date of birth (see Notes)
Houwing 2003
Methods Method of randomisation: use of a computer programme, balanced in blocks of four, by independent
person
Assessor blinding: nurse assessment blinded, but report states that supplements were “not exactly identical”
Intention-to-treat analysis: probably - appears so
Lost to follow-up: probably none
Participants Location: three centres, Arnhem, Deventer and Nieuwegein, in The Netherlands
Period of study: April 1998 to December 1999
103 participants
Inclusion criteria: hip fracture, pressure ulcer score >8 (DutchConsensusMeeting scoring system), consent
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Houwing 2003 (Continued)
from patient or legal representative
Exclusion criteria: terminal care, metastatic hip fracture, insulin-dependent diabetes, renal disease, hepatic
disease, morbid obesity (BMI > 40), therapeutic diet incompatible with supplementation, pregnancy,
lactation
Sex: 84 female, 19 male
Age: mean age 81 years
Fracture type: not given (48 internal fixation, 44 hemi-arthroplasty)
Interventions Timing of intervention: supplemented from immediately post-operative period for four weeks or until
discharge, given between regular meals
(a) 400 ml/day oral supplement (600 kcal or 2.51 MJ, 40 g protein, 6 mg arginine, 20 mg zinc, 500
mg vitamin C, 200 mg vitamin E as alpha-tocopherol, 4 mg carotenoids (Cubitan, NV Nutricia, The
Netherlands)); and regular diet
(b) Placebo supplement was a non-caloric, water-based drink with sweeteners, colourants and flavourings
in similar packaging, look and taste not identical to active supplement; and regular diet
Allocated: 51/52
Assessed: 51/52
Outcomes Length of follow-up: 28 days or earlier if discharged
Main outcomes:
Morbidity and complications: pressure sores
Other outcomes:Patient compliance: mean percentage intake/day, days supplemented
Notes Request for further details (method of randomisation, other complications, adverse events, length of stay,
further details of supplement)sent 13/10/03.
Details of randomisation method received 29/10/03.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Use of a computer programme, balanced in blocks of
four, by an independent person. Information from
trialist.
Madigan 1994
Methods Method of randomisation: not stated
Assessor blinding: not reported
Intention-to-treat analysis: not carried out, results presented for 30 participants of 34 randomised, results
from the two supplemented groups were combined
Lost to follow-up: details given
Participants Location: Illawarra Regional Hospital, Port Kembla Campus, Woolongong, Australia
Period of study: admissions from 6 September to 6 December 1993, 7 February to 31 March 1994
34 participants
Inclusion criteria: femoral neck fracture resulting from an accidental fall, age over 60 years, informed
consent
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Exclusion criteria: pathological fracture due to tumour; fracture due to violent external trauma; elective
total hip replacement; renal, hepatic, metastatic or endocrine (affecting skeletal metabolism)disease; ad-
mitted from nursing home; failure to gain consent; transferred to another hospital for surgery
Sex: 22 female, 8 male, of 30
Age: all over 60 years
Fracture type: further details not given
Interventions Timing of intervention: started on admission for 10 days, once daily after evening meal
(a) 250 ml oral supplement prepared by dietitian from ProMod (protein powder) and Polyjoule (glucose
polymer) providing 1.30 MJ or 310 kcal; 16 g protein, 41.4 g carbohydrate, 9.2 g fat, 0.19 mg riboflavin,
245 mg calcium, phosphorus 171 mg, and standard hospital diet.
(b) One multivitamin/mineral tablet daily (ELEVIT RDI, Roche) providing 750 mcg vitamin A, 1.1
mg thiamin, 1.7 mg riboflavin, 20 mg nicotinamide, 7 mg pantothenic acid, 1.9 mg pyridoxine, 2 mcg
vitamin B12, 200 mcg biotin, 200 mcg folic acid, 30 mg vitamin C, 200 IU vitamin D3, 15 IU vitamin
E, 125 mg calcium, 100 mg magnesium, 125 mg phosphorus, 5 mg iron, 1 mg copper, 1 mg manganese,
7.5 mg zinc 250 ml), plus oral supplement as above, and standard hospital diet
(c) Standard hospital diet
Allocated: ?/?/?
Assessed: 18/12 (a+b/c)
Outcomes Length of follow-up: 3 months post-discharge
Main outcomes:
Mortality
Morbidity and complications - numbers of complications (urinary infections, wound infections/delayed
healing, pressure sores, pneumonia, deep venous thrombosis, sepsis)
Length of stay: acute hospital
Postoperative functional status: number transferred to rehabilitation hospital, days to reach partial or full
weight bearing with support, days to reach independent mobility
Care required after discharge: discharge to home, hostel, nursing home, number of subjects returning to
pre-morbid mobility
Other outcomes:
Anthropometric indices: mid-upper arm circumference (*nr), triceps skinfold (*nr)
Nutritional indicators measured in blood: total lymphocyte count (*nr), albumin (*nr)
Other nutritional: total energy, protein, vitamin and mineral intakes from food and supplements
Patient compliance: number taking protein supplement for only 7 days
Notes In the trial report, the two supplemented groups were combined for analysis for comparison with control
group. Three subjects eliminated post-randomisation from analysis because only took protein supplement
for 7 days, and one eliminated for developing diabetes. Numbers of participants assigned/assessed not
always clear. Request for further details sent 4/2/00
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear No information: just states “randomised”.
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Miller 2006
Methods Method of randomisation: computer-generated sequence, stratified by admission accommodation. Sealed
opaque envelopes, prepared remote from recruitment by pharmacy
Assessor blinding: not reported
Intention-to-treat analysis: carried out
Lost to follow-up: details given
Participants Location: Orthopaedic wards of Flinders Medical Centre, Adelaide, Australia
Period of study: recruitment September 2000 to October 2002
43 hip fracture patients (out of a total of 51 with fall related lower limb fracture)*
Inclusion criteria: age 70 years or over, fall related lower limb fracture, resident in Southern Adelaide,
malnourished (< 25th percentile for mid-arm circumference for older Australians), written consent by
patient or next of kin.
Exclusion criteria: unable to understand instructions for positioning of upper arm, could not full weight
bear on side of injury > 7 days post admission, not independently mobile pre-fracture, medically unstable
> 7 days post admission, cancer, chronic renal failure, unstable angina, diabetes.
Sex (of 51): 42 female, 9 male
Age (of 51): mean 83 years.
Fracture type: not given (aside from hip fracture = 43)
Interventions Timing of intervention: from 7 days after fracture, given daily for 6 weeks
(a) Nutrition only intervention: Fortisip (Nutricia Australia Pty Ltd) oral protein and energy supplement
(1.5 kcal/ml, 16% protein, 35% fat, 49% carbohydrate)to provide 45% of estimated energy intakes. (
Individually prescribed and delivered.)Four doses of equal volume given by nurses from drug trolley,
continued after hospital discharge as twice per day or more. Once weekly visits on weeks 7 to 12.
(d) Attention control. Usual care and general nutrition and exercise advice. Twice weekly visits on weeks
1 to 6, once weekly on weeks 7 to 12.
Allocated: 23/20
Assessed: 23/20 (mortality)
Outcomes Length of follow-up: 12 months
Main outcomes:
Mortality (for participants with hip fracture)
Length of hospital stay (acute, rehabilitation, total) (not available for participants with hip fracture)
Other outcomes:
Weight loss (not available for participants with hip fracture)
Notes Trial population also included 49 other participants (43 with hip fracture), who were allocated to the
two other intervention groups: exercise; and nutrition plus exercise. Data from these two groups are not
included in this review.
Email to Professor Crotty 14 January 2009 asking for data for participants with hip fracture only; mortality
data provided 20th February 2009.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes “The Pharmacy departmentmaintained a computer
generated allocation sequence in sealed opaque en-
velopes.”
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Neumann 2004
Methods Method of randomisation: not stated, stratified by type of hip fracture
Assessor blinding: not reported
Intention-to-treat analysis: unclear
Lost to follow-up: details given
Participants Location: 3 rehabilitation hospitals, USA
Period of study: unclear
46 participants
Inclusion criteria: within 3 weeks of surgical repair of hip fracture (intertrochanteric or femoral neck),
expected to stay 1-3 weeks in rehabilitation, aged 60 years or over, BMI < 30 kg/m2, informed consent,
able to be reached by phone after discharge
Exclusion criteria: fracture due to non-osteoporotic disease, e.g. pathological fracture; significant trauma
to other organ systems or medical conditions significantly affecting outcome (severe hepatic dysfunction
bilirubin > 3mg/dL, severe renal dysfunction creatinine at least 3mg/dL or dialysis, uncontrolled diabetes:
2 random blood glucose values > 200 mg/dL or > 140 mg/dL fasting)
Sex: 33 female, 13 male
Age: mean age 83 years
Fracture type: not given
Interventions Timing of intervention: consecutive 28 day period at least two 8 oz cans/day
(a) Boost HP high protein liquid supplement (Mead Johnson, Evansville, Indiana, USA) providing per
8 oz can: 240 kcal, 15 g protein, 33 g carbohydrate, 6 g fat, 1110 IU vitamin A, 89 IU vitamin D,
6.7 IU vitamin E, 27 mcg vitamin K, 13.3 mg vitamin C, 89 mcg folic acid, 0.33 mg thiamin, 0.4 mg
riboflavin, 0.47 mg vitamin B6, 1.33 mcg vitamin B12, 4.7 mg niacin, 56 mg choline, 67 mcg biotin,
2.3 mg pantothenic acid, 220 mg sodium, 490 mg potassium, 350 mg chloride, 240 mg calcium, 220
mg phosphorus, 90 mg magnesium, 33mg iodine, 0.67 mg manganese, 0.47 mg copper, 3.3 mg zinc, 4
mg iron, 15.8 mcg selenium, 27 mcg chromium, 16.9 mcg molybdenum
(b) Ensure liquid supplement (Ross Labs, Columbus, Ohio, USA) providing per 8 oz can: 250 kcal, 8.8
g protein, 40 g carbohydrate, 6.1 g fat, 1250 IU vitamin A, 100 IU vitamin D, 7.5 IU vitamin E, 20
mcg vitamin K, 30 mg vitamin C, 100 mcg folic acid, 0.38 mg thiamin, 0.43 mg riboflavin, 0.50 mg
vitamin B6, 1.50 mcg vitamin B12, 5.0 mg niacin, 100 mg choline, 75 mcg biotin, 2.5 mg pantothenic
acid, 200 mg sodium, 370 mg potassium, 310 mg chloride, 300 mg calcium, 300 mg phosphorus, 100
mg magnesium, 38 mcg iodine, 1.3 mg manganese, 0.50 mg copper, 3.8 mg zinc, 4.5 mg iron, 18 mcg
selenium, 30 mcg chromium, 38 mcg molybdenum
Allocated: 22/24
Assessed: 18/20 for length of stay
Outcomes Length of follow-up: 3 months
Main outcomes:
Mortality
Morbidity: complications (*nr), adverse events (*nr)
Length of rehabilitation hospital stay
Location for discharge
Postoperative functional status: mobility subscale of FIM instrument (Uniform Data System for Medical
Rehabilitation)
Other outcomes:
Nutritional indicators measured in blood: albumin (subgroup data)
Other nutritional: days of supplement consumption
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Notes Request for further details (deaths, denominators for length of stay, complications)sent 13/10/04. Details
of deaths and denominators received 06/01/05
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear No information on safeguards: “randomized, dou-
ble-blind, parallel-group study”
Schürch 1998
Methods Method of randomisation: states random number table and double-blind study, but unclear if those who
assigned were blinded
Assessor blinding: unclear, no report of when code broken
Intention-to-treat analysis: unclear
Lost to follow-up: incomplete report of drop outs
Participants Location: orthopaedic ward in hospital and recovery hospital, Geneva, Switzerland
Period of study: April 1992 to February 1994
82 participants
Inclusion criteria: hip fracture within 2 weeks attributable to osteoporosis (minor trauma), aged over 60
years, able to give written consent
Exclusion criteria: pathological fracture; fracture caused by severe trauma; history of contralateral hip
fracture; severe mental impairment; active metabolic bone disease; renal failure (plasma creatinine equal to
or greater than 200 mcmol/L); acute illness that could interfere with study protocol; severe malnutrition
(serum albumin less than 15 g/L); on drugs known to alter bone metabolism, e.g. calcitonin, fluoride, sex
hormones, corticosteroids, bisphosphonates; life expectancy less than 1 year
Sex: 74 female, 8 male
Age: mean 80.7 years
Fracture type: 31 cervical, 51 trochanteric
Interventions Timing of intervention: mean randomisation time 6.5 (SD 1.9) days after fracture, supplemented 5 days
a week for 6 months
(a) Oral protein supplement (1.05 MJ or 250 kcal, 20 g protein, 3.1 g fat, 35.7 g carbohydrate, 1000
IU vitamin A, 30 mcg vitamin K1, 20 mg vitamin C, 550 mg calcium, 91 mg magnesium, 429 mg
phosphorus, 228 mg sodium) plus oral 200,000 IU vitamin D3 once at baseline during study
(b) Placebo without protein made isocaloric by addition of maltodextrins, plus oral 200,000 IU vitamin
D3 once at baseline during study
Allocated: 41/41
Assessed: ?/?
Outcomes Length of follow-up: 12 months
Main outcomes:
Mortality
Length of stay: orthopaedic ward, rehabilitation stay
Postoperative functional status: activities of daily living score
Putative side effects: drop outs due to nausea and diarrhoea
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Schürch 1998 (Continued)
Other outcomes:
Anthropometric indices: body weight, whole body lean and fat mass, all (*nr)
Fractures : vertebral deformity
Bone mineral density: anteroposterior and lateral lumbar spine, femoral neck, trochanter, proximal femur,
femoral shaft, whole body
Nutritional indicators measured in blood: albumin, prealbumin, insulin like growth factor I
Functional markers of nutritional status: biceps muscle strength, cell mediated immunity, hand grip (*nr)
Patient compliance: refusals
Notes Composition of placebo unclear, denominators not clear. Request for further details sent 27/5/99, resent
7/2/00
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear “Using a random number table, we assigned ...”
Although “double-blind”, it is unclear whether al-
location was concealed.
Stableforth 1986
Methods Method of randomisation: not stated
Assessor blinding: not reported
Intention-to-treat analysis: 3 excluded, intention-to-treat analysis not possible
Lost to follow-up: none
Participants Location: hospital, Bristol, UK
Period of study: not given
61 participants
Inclusion criteria: people with hip fracture within 12 hours of fracture, women over 65 years
Exclusion criteria: none given
Sex: all female
Age: Mean 81.8 years, range 65-96 years
Fracture type: 23 trochanteric, 35 subcapital hip fractures (others not specified)
Interventions Timing of intervention: started after surgery and 24 to 36 hours of crystalloid intravenous fluids. Inter-
vention provided during waking hours for 10 days.
(a) Encouraged to drink flavoured, Carnation Instant Breakfast in 300 ml milk (1.34 MJ or 320 kcal,
18.5 g protein, 11 g fat, 40 g carbohydrate, vitamins and minerals) plus ward diet
(b) Ward diet alone
Allocated: ?/? 61 in all
Assessed: ?/? 61 in all
Outcomes Length of follow-up: 4 weeks
Main outcomes:
Mortality: all causes
Morbidity and complications: anaesthetic, surgical infection, gastrointestinal, urinary
Other outcomes:
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Stableforth 1986 (Continued)
Anthropometric indices: weight
Other nutritional: energy balance, nitrogen balance
Notes Limited functional outcomes.
Request for further details, especially on longer term follow-up, sent 13/4/99, resent 7/2/00
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear No information: “randomly selected group”
Sullivan 1998
Methods Method of randomisation: sealed opaque envelopes opened sequentially
Assessor blinding: not reported
Intention-to-treat analysis: appears so
Lost to follow-up: none, all participants accounted for
Participants Location: acute care facility, Little Rock, USA
Period of study: recruitment over 5 months, probably prior to 1998
18 participants
Inclusion criteria: aged over 64 years, acute hip fracture requiring surgery, admitted Monday to Friday
Exclusion criteria: unable to gain consent from patient or guardian, pathological fracture (cancer or non-
osteoporotic), significant other system trauma, metastatic cancer, cirrhosis, contraindication to enteral
feeding, organ failure
Sex: 1 female, 17 males
Age: mean 75.6 years
Fracture type: femoral neck or intertrochanteric
Interventions Timing of intervention: small-bore nasogastric feeding tube placed in theatre or recovery room. Feeding
started postoperatively, nightly from 19.00 hours, until volitional intake greater than 90% of predicted
requirements for 3 consecutive days or participant discharged home.
(a) Nasogastric feeding via small bowel (or more proximally if low risk of aspiration): 1375 ml of polymeric
enteral formula (Promote, Ross Laboratories, 85.8 g protein, 4.31 MJ or 1031 kcal non-nitrogenous
energy, 71.5 g carbohydrate, 35.8 g fat, 88 mcg vitamin K, 77 mcg selenium, 110 mcg chromium, 165
mcg molybdenum, 165 mg carnitine, 165 mg taurine), given at 125 ml/h over 11 hours, plus standard
care of 3 meals daily
(b) Standard care of 3 meals daily
Allocated: 8/10
Assessed: 8/7 for discharge statistics
Outcomes Length of follow-up: 6 months
Main outcomes:
Mortality: in hospital and at 6 months
Morbidity and complications: postoperative life-threatening and minor complications
Length of stay: total acute care stay for survivors
Postoperative functional status: mini mental state exam score, Katz index of activities of daily living
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Sullivan 1998 (Continued)
Care required after discharge: discharge to institution, total number of medications
Putative side effects of treatment: gastrointestinal
Other outcomes:
Nutritional indicators measured in blood: albumin, transferrin
Other nutritional: average daily volitional energy intake over first 7 postoperative days
Notes Pilot study.
Request for further details (such as control group denominators)sent. Reply from trialist (10/2/00) gave
further details of randomisation, place of care, complications, deaths, volitional food intake, nature of
fracture, and content of supplement
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes “The actual randomization was prepared by the bio-
statistician.. using sealed envelopes. Security (lined)
envelopes were used to assure that the assignment
cannot be read without opening the envelope. After
consent had been obtained and the baseline assess-
ment was completed, the next envelope was opened
to reveal the group assignment ...” Information from
trialist.
Sullivan 2004
Methods Method of randomisation: sealed opaque envelopes opened sequentially
Assessor blinding: not reported
Intention-to-treat analysis: appears so
Lost to follow-up: details given
Participants Location: orthopaedic wards of University Hospital and Department of Veteran’s Affairs Hospital, Little
Rock, Arkansas, USA
Period of study: recruitment June 1996 to October 1997
57 participants
Inclusion criteria: over 64 years, acute femoral neck or intertrochanteric fracture treated surgically
Exclusion criteria: incapable of informed consent and no legal guardian, pathological fracture (cancer
or not osteoporotic), significant trauma to other organ systems (e.g. motor vehicle accident), metastatic
cancer, cirrhosis, enteral feeding contraindicated (e.g. short bowel), organ failure making intervention
inappropriate
Sex: 18 female, 39 male
Age: mean age 79 years
Fracture type: 19 required endoprosthesis
Interventions Timing of intervention: small bore feeding tube placed within 12 hours of surgery, confirmed by x-ray in
place until deficit between requirements and oral intake < 480 kcal/day for at least 2 consecutive days or
until discharged. Given nightly over 11 hours.
(a) Harris-Benedict equation with stress and activity factors used to predict requirements to make up
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Sullivan 2004 (Continued)
deficit after food intake calculated - given as Promote (Ross Laboratories), 1000 kcal, 62.5 g protein, 130
g carbohydrate, 26 g fat per litre, if deficit > 480 kcal/day. If deficit 240-480 kcal/day, participant asked to
drink supplement instead of tube feeding. Tube feeding begun at 50 ml/hour and increased by 25 ml/hour
to maximum of 125 ml/hour. Given with standard care.
(b) Standard care
Allocated: 27/30
Assessed: 27/30
Outcomes Length of follow-up: 6 months
Main outcomes:
Mortality
Morbidity: postoperative and postoperative life-threatening complications, diarrhoea
Length of hospital stay
Level of care: discharge to an institution, medications at discharge
Postoperative functional status: Katz index of activities of daily living, Mini Mental State Exam score
Other outcomes:
Nutritional indicators measured in blood: albumin, pre-albumin
Other nutritional: energy intake
Notes Request for further details on randomisation and tube feeding sent 15/03/06. Reply, received 14/04/06,
gave further details of randomisation method.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes “The randomization process was prepared by the
biostatistician, using a series of sealed envelopes. Se-
curity (lined) envelopes were used to assure that the
assignment could not be read without opening the
envelope. After consent had been obtained and the
baseline assessment was completed, the next enve-
lope in order was opened to reveal the group assign-
ment. Each envelope contained a card. The card had
the assignment for treatment or control pre-printed.
Space was provided to enter the patient name and
ID as well as the date, time and person responsible
for randomization. The study nurse completed the
card, photocopied it, and returned the original to
the biostatistician as a check that the randomization
process was progressing appropriately. Subjects were
randomized to either treatment or control within
blocks to assure that there were roughly equal num-
bers of subjects in each group at the end of the study.
The block sizes were randomly varied to minimize
the ability to deduce the assignment for a particular
patient before opening the envelope.” Reply from
trialist.
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Tidermark 2004
Methods Method of randomisation: numbered opaque sealed envelopes, unclear if randomisation fully concealed
since the envelopes prepared and opened by the same research nurse
Assessor blinding: not reported
Intention-to-treat analysis: appears so
Lost to follow-up: details given
Participants Location: hospital(s) in Stockholm, Sweden
Period of study: before October 2002
40 participants
Inclusion criteria: age at least 70 years, BMI 24 kg/m2 or less, not institutionalised, absence of severe
cognitive dysfunction, independent walking with or without walking aids
Exclusion criteria: fracture not suitable for internal fixation, displaced fracture older than 24 hours at time
of arrival in emergency room, rheumatoid arthritis, radiographic osteoarthritis
Sex: all female
Age: mean age 84 years
Fracture type: 40 femoral neck (24 displaced)
Interventions Timing of intervention: 6 months, unclear when started
(a) Fortimel protein rich liquid oral supplement, 20 g protein/200 ml, unclear if 200 or up to 400 ml/day
(b) Standard treatment
(c) Nandrolone decanoate (anabolic steroid) 25 mg intramuscular injection/3 weeks and Fortimel as in
(a): group not included in review
Allocated: 20/20
Assessed: 20/20 for mortality
Outcomes Length of follow-up: 12 months
Main outcomes:
Mortality
Morbidity and complications: deep infection, urinary tract infection, fracture healing complication
Length of hospital stay
Activities of daily living: Katz score, mobility
Quality of life: EuroQol
Fracture healing
Adverse events
Other outcomes:
Changes in anthropometric indices: weight, BMI, lean body mass, fat mass
Changes in nutritional indicators measured in blood: albumin, C-reactive protein, (IGF-I) insulin-like
growth factor-I, (IGFBP-I) IGF-binding protein I
Bone mineral density
Functional markers of nutritional status: hand grip strength
Patient compliance
Notes Request for further details (complications)sent. Reply from trialist (14/10/04) gave further details of
infections. Request for further details (randomisation)sent. Reply from trialist (10/11/04) gave full details
of randomisation process.
Risk of bias
Item Authors’ judgement Description
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Tidermark 2004 (Continued)
Allocation concealment? Unclear “Patients were randomised, using opaque sealed en-
velopes”. (Also numbered.)However, the envelopes
were prepared and opened by the same research
nurse, involved in the trial.
Tkatch 1992
Methods Method of randomisation: not stated
Assessor blinding: not reported
Intention-to-treat analysis: not carried out, at least 6 participants excluded after randomisation
Lost to follow-up: none, all participants accounted for
Participants Location: orthopaedic ward, hospital and recovery hospital, Geneva, Switzerland
Period of study: 17 consecutive weeks, probably prior to 1992
72 participants
Inclusion criteria: subcapital or trochanteric fracture of the proximal femur following moderate trauma,
aged over 60 years
Exclusion criteria: fracture resulting from violent injury, primary or metastatic bone tumour; renal os-
teodystrophy; hepatic insufficiency; endocrine disorders affecting skeletal metabolism; chronic alcoholism;
advanced dementia; contralateral reunited hip fracture; refusal to participate; corticosteroid, fluoride,
phenytoin treatment; Paget’s disease; non residence in Geneva, left orthopaedic unit prematurely after
conservative treatment for subcapital fracture
Sex: 54 female, 8 male, of 62
Age: mean age 82 years
Fracture type: 32 subcapital, 30 trochanteric
Interventions Timing of intervention: started on admission to orthopaedic clinic, continued in recovery hospital. Given
once daily at 20.00 hours
(a) Protein supplement (20.4 g protein from milk) in 250 ml of oral supplement (5.8 g fat, 29.5 g
carbohydrate, 525 mg calcium, 70 mg magnesium, 270 mg phosphorus, 25 IU vitamin D3, 750 IU
vitamin A)
(b) 250 ml of oral supplement alone
Allocated: ?/?
Assessed: 33/29
Outcomes Length of follow-up: 7 months
Main outcomes:
Mortality
Morbidity and complications: complications (bedsore, anaemia, cardiac failure, infection, digestive dis-
turbance, other), favourable clinical course (excludes death, major complication, or two or more minor
complications)
Length of stay: orthopaedic ward and recovery hospital
Care required after discharge: still in hospital at 7 months, returned home at 7 months
Other outcomes:
Fractures: hip and other fractures
Bone mineral density: femoral neck, femoral shaft, lumbar spine
Nutritional indicators measured in blood: albumin (*nr)
Patient compliance: non compliance taking supplement, controls taking protein supplement
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Tkatch 1992 (Continued)
Notes Post-randomisation exclusions: 3 in protein intervention group excluded for non-compliance, 3 controls
excluded (2 took protein supplements, one severe diarrhoea), 4 of unspecified group left orthopaedic unit
prematurely. Numbers of complications unclear. Request for further details (exclusions, complications)
sent 24/5/99, resent 7/2/00
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear No information: just “randomized into twogroups”.
BMI: body mass index
NHS: UK National Health Service
mosmol/L: milliosmoles/L, a measure of osmolality
*nr: no results
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Ashworth 2006 Pilot study for randomised controlled trial of snacks versus oral nutritional supplements. Trial stopped early
as only four out of 95 patients were eligible for recruitment. No relevant outcomes.
Bachrach 2000 Randomised controlled trial of total hip arthroplasty versus osteosynthesis for hip fracture, but not of nutri-
tional supplementation. The second half of each surgical treatment group received nutritional supplementa-
tion; thus, the supplementation and control groups were also not concurrent.
Bachrach 2001 Study of protein and energy supplementation after hip fracture. Not a randomised controlled trial: non
concurrent study groups.
Beringer 1986 Randomised controlled trial. Comparison between 880 mg calcium and 80mg calciumwith 5mg of anabolic
steroid stanozolol. Not both nutrition interventions, and required outcomes not evaluated.
Boudville 2002 Short-term study the effect on the appetite of 250 kcal supplement of people with hip or pelvic fracture.
Unclear if randomised controlled trial. No relevant outcomes.
Bradley 1995 Not a randomised controlled trial: nursing education programme targeting specific problems including
nutritional deficits.
Brocker 1994 The 194 ambulatory elderly participants in the trial are unlikely to include people with hip fracture. No
response from author.
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(Continued)
Carlsson 2005 Randomised controlled trial of protein-rich liquid supplement versus supplement with nandrolone decanoate
injections. Not in scope of review.
Crossley 1977 Unable to contact author. Contacted project supervisor, thesis no longer available.
Gegerle 1986 Randomised controlled trial of 250 ml oral supplement providing 20 g protein, 254 kcal, minerals and
vitamins. Study reports only effects of supplement on intake of intervention group, compared to control
group. No other outcomes provided. French paper - checked by French translator.
Giaccaglia 1986 Not a randomised controlled trial. Italian paper - checked by Italian translator.
Goldsmith 1967 Not people with hip fracture.
Groth 1988 Not people with hip fracture nor a randomised controlled trial.
Harju 1989 Comparison of 0.25mcg 1-alpha-hydroxyvitaminD3, 100 IU calcitonin and placebo in women after femoral
neck fracture. No outcomes of interest given, possibly not a randomised controlled trial.
Harwood 2004 Randomised controlled trial, involving 150 women after hip fracture, comparing single injection of 300,000
IU vitamin D2, injected vitamin D2 and 1000 mg/d oral calcium, 800 IU/d oral vitamin D3 and 1000 mg/d
calcium, or no treatment. Secondary prevention trial.
Hedström 2002 Randomised controlled trial, involving 63 women after hip fracture, comparing nandrolone decanoate (25
mg intramuscularly every three weeks), 0.25 mcg 1-alpha-hydroxyvitamin D3 daily and 500 mg calcium
daily versus 500 mg calcium daily. Thus this evaluated anabolic steroid and vitamin D together.
Hommel 2007 Quasi-experimental before and after study of best practices for people with hip fracture, with nutritional
drink as one component of the intervention (clinical pathway).
Kacmaz 2007 Non-randomised comparison of bran supplements and nursing intervention versus usual nursing care in
post-operative orthopaedic patients, mean age 69 years. Unclear if any patient had hip fracture.
Kuzdenbaeva 1981 Comparative study, not explicitly randomised. Mixed group of hip fracture and femoral shaft fracture par-
ticipants aged 17 to 67 years; thus majority of hip fracture participants were not over 65 years. Russian paper
- checked by Russian translator.
Larsson 1990 Randomised trial of older people, of whom 89 had fractures, newly admitted to long-term medical care. No
response from lead author to requests for separate results for participants with hip fracture.
Lauque 2000 Randomised controlled trial of protein and energy supplementation in nursing homes; not specifically directed
at people after hip fracture.
Lawson 2003 Not a randomised controlled trial. Mixed group of orthopaedic patients.
Moller-Madsen 1988 No usable results published in conference abstract reporting trial of oral supplements for 25 people with hip
fracture. No response from authors.
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(Continued)
Nusbickel 1989 No response from author. No information in the two conference abstracts reports of the trial of how many
people with hip fracture were included, nor their results.
Oloffson 2007 Randomised trial of a multidisciplinary intervention programme for people after hip fracture. The nutritional
intervention was only one component of the complex intervention.
Pedersen 1999 Intervention and control groups were not concurrent, nor randomised. The trial investigated the effects of
active involvement of orthopaedic patients in their own dietary care; thus the intervention was not direct
nutritional supplementation but rather a means of enhancing update by patients. Mixed patient population
with hip fracture, or undergoing knee or hip arthroplasty.
Ravetz 1959 Two hip fracture patients only. Unlikely to be a randomised controlled trial.
Shaikhiev 1984 Comparative study, not explicitly randomised. Mixed group of hip fracture and femoral shaft fracture par-
ticipants aged 17 to 65 years; thus majority of hip fracture participants were not over 65 years. Russian paper
- checked by Russian translator.
Stumm 2001 Randomised controlled trial testing the addition of pear juice or high fibre supplement to normal diet versus
normal diet alone in a mixed group of orthopaedic patients admitted for elective surgery or after traumatic
fracture. Aimed at themanagement of constipation and not for improvement of nutritional status; no relevant
outcomes.
Tassler 1981 Not randomised controlled trial. German paper.
Taylor 1974 Quasi-randomised placebo-controlled trial of vitamin C: patients recruited with pressure sores, not because
of hip fracture, although nine out of 20 participants had hip fracture.
Thomas 2008 Randomised controlled trial of resistance training and nutrition therapy combined versus attention control.
Unable to assess effect of nutrition separately.
Volkert 1996 Randomised controlled trial involving a mixed group of medical, general surgical and orthopaedic patients
aged over 75 years. Author indicates that only a few participants had hip fractures.
Williams 1989 This trial appears to form part of one of three consecutive studies published in the PhD thesis of Driver
(Driver LT. Evaluation of supplemental nutrition in elderly orthopaedic patients [PhD thesis]. Surrey (UK):
Univ. of Surrey, 1994). All three studies evaluated nutritional supplementation in a combined group of hip
fracture and elective hip replacement patients. There were major defects in the randomisation process, as well
as numerical discrepancies, which suggest intention to treat problems.We have been unable to contact Driver
to obtain clarification of the status of the three studies, the trial populations and further specific information
on the participants with hip fracture. For the purposes of this review, the three studies have been represented
as one trial.
Wong 2004 Randomised controlled trial of dietetic counselling versus usual care in amixedpatient groupwith osteoporotic
fractures (forearm, vertebral, hip). Limited outcomes only (energy, protein and calcium intake, weight and
BMI)
Zauber 1992 Randomised controlled trial. Mixed group of elective hip replacement and hip fracture patients. Some
participants were excluded from the analysis. Limited outcomes only (haemoglobin and reticulocyte count).
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Characteristics of studies awaiting assessment [ordered by study ID]
Gerstorfer 2008
Methods Controlled trial: “randomly divided”
Participants 46 women with hip fracture, mean age 83 years
Interventions (a) Nutritional therapeutic regime (protocols, protein enriched food, oral and/or parenteral supplementation).
(b) Usual care.
Outcomes Nutritional biochemistry
Notes Email to Dr Elmadfa on 3rd October 2008 asking for further details
Stratton 2006
Methods Randomised controlled trial
Participants 50 men and women with fractured neck of femur, at risk of malnutrition
Interventions (a) Liquid multinutrient oral nutritional support.
(b) Food snacks.
Outcomes Compliance, patient satisfaction
Notes Email to Dr Stratton on 3rd October 2008 asking for further details
Characteristics of ongoing studies [ordered by study ID]
Cameron
Trial name or title Effectiveness of oral supplementation for older women with hip and other fractures (EONS)
Methods Randomised controlled trial.
Participants 43 older women with hip or other fractures.
Interventions (a) Oral nutritional supplementation: 235 ml (1.5 kcal/ml) daily for 40 days.
(b) Usual care.
Outcomes Follow-up: 1 and 4 months post fracture.
Outcomes: ADL function, nutritional status and medical complications
Starting date Started April 2000. Recruitment completed and follow-up completed.
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Cameron (Continued)
Contact information Prof Ian Cameron
Rehabilitation Studies Unit
University of Sydney
PO Box 6
Ryde
New South Wales AUSTRALIA
NSW 1680
Telephone: +61 2 9808 9236
Facsimile: +61 2 9809 9037
E-mail:
ianc@mail.usyd.edu.au
Notes Randomised using sealed opaque envelopes with sequence generated from random number table. Updated
information received from Ian Cameron in July 2003; when 43 trial participants had completed follow-up.
Study completion confirmed by Ian Cameron in October 2004.
Analysis ongoing confirmed by Ian Cameron October 2008.
Dagnelie
Trial name or title Effectiveness and cost-effectiveness of nutritional screening and intervention in elderly subjects after hip
fracture
Methods Randomised controlled trial
Participants People aged 55 years or older with hip fracture from three centres in The Netherlands
Interventions (a) Protein and energy enriched oral nutritional supplements and regular dietetic counselling during hospi-
talisation and after discharge at participants’ homes for 3 months.
(b) Usual nurse and dietetic care.
Outcomes Follow-up: 3 and 6 months after trial inclusion
Outcomes: total length of stay in hospital and rehabilitation, functional status, quality of life, costs, informal
care, complications, nutritional status
Starting date August 2007, due to complete August 2009 for primary outcome measure
Contact information Dr PC Dagnelie and Dr PLM Reijven
Maastricht University
The Netherlands
Contacts:caroline.wyers@epid.unimaas.nl; p.reijven@epid.unimaas.nl
Notes
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Houdijk
Trial name or title The effect of taurine on morbidity and mortality in the elderly hip fracture patient
Methods Randomised controlled double-blind trial
Participants Aged over 75 years, surgery for hip fracture, both genders
Interventions (a) 3 g taurine / day or 6 g taurine / day
(b) placebo
Outcomes Follow-up: 1 year
Outcome: morbidity and mortality
Starting date July 2007, expected completion July 2010
Contact information Dr Alexander PJ Houdijk
Medical Center Alkmaar
Alkmaar
Noord-Holland
1800 AM
The Netherlands
Telephone: +31 72 5484444 ext: 5383
E-mail: a.p.j.houdijk@mca.nl
Notes
Miller
Trial name or title Does a high dose fish oil intervention improve outcomes in older adults recovering from hip fracture?
Methods Randomised controlled double-blind trial
Participants 150 men and women, aged 65 years or over, after surgical fixation of femoral fracture, history of recent
unexplained weight loss and at risk of further weight loss and current poor appetite, elevatedC reactive protein
(6 mg/L or more), serum albumin < 35 g/L, raised energy expenditure.
Interventions (a) 15 ml/day liquid fish oil orally (4.9 g eicosapentaenoic acid and 3.4 g docosahexaenoic acid) and individ-
ualised nutrition therapy.
(b) Low-dose plant and fish oil supplement 15 ml/day (0.49 g eicosapentaenoic acid and 0.39 g docosahex-
aenoic acid) and individualised nutrition therapy.
Both for 12 weeks.
Outcomes Follow-up: 6 and 12 weeks
Outcome: health related quality of life, physical function, nutritional status, resting energy expenditure,
inflammatory markers.
Starting date February 2010
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Miller (Continued)
Contact information Dr Michelle Miller
Department of Nutrition and Dietetics
Flinders University
GPO Box 2100
Adelaide SA 5001
Australia
E-Mail: michelle.miller@flinders.edu.au
Notes
ADL: activities of daily living
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D A T A A N D A N A L Y S E S
Comparison 1. Multinutrient supplement (oral, nasogastric, intravenous) versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality by end of study 14 887 Risk Ratio (M-H, Fixed, 99% CI) 0.77 [0.51, 1.15]
1.1 Oral supplements 9 470 Risk Ratio (M-H, Fixed, 99% CI) 0.76 [0.42, 1.37]
1.2 Nasogastric tube feeding 3 280 Risk Ratio (M-H, Fixed, 99% CI) 0.99 [0.50, 1.97]
1.3 Nasogastric tube feeding
and oral supplements
1 57 Risk Ratio (M-H, Fixed, 99% CI) 0.74 [0.23, 2.35]
1.4 Intravenous feeding and
oral supplements
1 80 Risk Ratio (M-H, Fixed, 99% CI) 0.11 [0.01, 2.00]
2 Patients with complications at
end of study
9 454 Risk Ratio (M-H, Fixed, 99% CI) 0.71 [0.57, 0.89]
2.1 Oral supplements 6 299 Risk Ratio (M-H, Fixed, 99% CI) 0.81 [0.58, 1.13]
2.2 Nasogastric tube feeding 1 18 Risk Ratio (M-H, Fixed, 99% CI) 1.09 [0.73, 1.64]
2.3 Nasogastric tube feeding
and oral supplements
1 57 Risk Ratio (M-H, Fixed, 99% CI) 1.11 [0.75, 1.65]
2.4 Intravenous feeding and
oral supplements
1 80 Risk Ratio (M-H, Fixed, 99% CI) 0.21 [0.10, 0.46]
3 Patients with complications at
end of study: random-effects
model
9 454 Risk Ratio (M-H, Random, 99% CI) 0.73 [0.47, 1.12]
3.1 Oral supplements 6 299 Risk Ratio (M-H, Random, 99% CI) 0.86 [0.62, 1.20]
3.2 Nasogastric tube feeding 1 18 Risk Ratio (M-H, Random, 99% CI) 1.09 [0.73, 1.64]
3.3 Nasogastric tube feeding
and oral supplements
1 57 Risk Ratio (M-H, Random, 99% CI) 1.11 [0.75, 1.65]
3.4 Intravenous feeding and
oral supplements
1 80 Risk Ratio (M-H, Random, 99% CI) 0.21 [0.10, 0.46]
4 Unfavourable outcome (death or
complications) at end of study
4 229 Risk Ratio (M-H, Fixed, 99% CI) 0.76 [0.55, 1.04]
4.1 Oral supplements 4 229 Risk Ratio (M-H, Fixed, 99% CI) 0.76 [0.55, 1.04]
4.2 Nasogastric tube feeding 0 0 Risk Ratio (M-H, Fixed, 99% CI) Not estimable
4.3 Nasogastric tube feeding
and oral supplements
0 0 Risk Ratio (M-H, Fixed, 99% CI) Not estimable
4.4 Intravenous feeding and
oral supplements
0 0 Risk Ratio (M-H, Fixed, 99% CI) Not estimable
5 Unfavourable outcome (death or
complications) at end of study:
random-effects model
4 229 Risk Ratio (M-H, Random, 99% CI) 0.71 [0.41, 1.22]
5.1 Oral supplements 4 229 Risk Ratio (M-H, Random, 99% CI) 0.71 [0.41, 1.22]
5.2 Nasogastric tube feeding 0 0 Risk Ratio (M-H, Random, 99% CI) Not estimable
5.3 Nasogastric tube feeding
and oral supplements
0 0 Risk Ratio (M-H, Random, 99% CI) Not estimable
5.4 Intravenous feeding and
oral supplements
0 0 Risk Ratio (M-H, Random, 99% CI) Not estimable
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6 Unfavourable outcome (death
or complications) - oral
supplements extra analyses
4 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
6.1 Oral supplements: worst
case scenario
4 238 Risk Ratio (M-H, Fixed, 99% CI) 0.85 [0.62, 1.15]
6.2 Oral supplements:
Hankins 1996 acute hospital
data
1 31 Risk Ratio (M-H, Fixed, 99% CI) 0.96 [0.71, 1.31]
6.3 Oral supplements:
Hankins 1996 post discharge
1 31 Risk Ratio (M-H, Fixed, 99% CI) 1.10 [0.50, 2.41]
Comparison 2. Multinutrient supplements (oral, nasogastric routes, intravenous) versus control (split by nutri-
tional status)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality by end of study 14 887 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.51, 1.15]
1.1 Malnourished targeted 4 206 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.25, 1.07]
1.2 Malnourished not targeted 10 681 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.56, 1.53]
2 Patients with complications at
end of study
9 454 Risk Ratio (M-H, Fixed, 99% CI) 0.71 [0.57, 0.89]
2.1 Malnourished targeted 1 29 Risk Ratio (M-H, Fixed, 99% CI) 0.59 [0.23, 1.49]
2.2 Malnourished not targeted 8 425 Risk Ratio (M-H, Fixed, 99% CI) 0.72 [0.57, 0.91]
3 Unfavourable outcome (death or
complications) at end of study
4 229 Risk Ratio (M-H, Fixed, 99% CI) 0.76 [0.55, 1.04]
3.1 Malnourished targeted 1 29 Risk Ratio (M-H, Fixed, 99% CI) 0.47 [0.17, 1.31]
3.2 Malnourished not targeted 3 200 Risk Ratio (M-H, Fixed, 99% CI) 0.81 [0.58, 1.12]
Comparison 3. Multinutrient supplements (oral, nasogastric routes, intravenous) versus control (by allocation
concealment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality by end of study
(concealed? = yes; unclear; no)
14 887 Risk Ratio (M-H, Fixed, 99% CI) 0.77 [0.51, 1.15]
1.1 Allocation concealed 5 239 Risk Ratio (M-H, Fixed, 99% CI) 0.39 [0.18, 0.85]
1.2 Unclear if allocation
concealed
6 407 Risk Ratio (M-H, Fixed, 99% CI) 1.22 [0.65, 2.28]
1.3 Allocation not concealed
(quasi-randomised)
3 241 Risk Ratio (M-H, Fixed, 99% CI) 0.78 [0.34, 1.79]
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Comparison 4. High protein containing supplements versus low protein or non-protein containing supplements
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality by end of study 4 361 Risk Ratio (M-H, Fixed, 99% CI) 1.42 [0.85, 2.37]
1.1 Protein containing
supplement v non-protein
containing supplement
3 315 Risk Ratio (M-H, Fixed, 99% CI) 1.38 [0.82, 2.34]
1.2 High protein containing
supplement v low protein
containing supplement
1 46 Risk Ratio (M-H, Fixed, 99% CI) 2.18 [0.21, 22.42]
2 Unfavourable outcome (death or
complications) at end of study
2 223 Risk Ratio (M-H, Fixed, 99% CI) 0.78 [0.65, 0.95]
2.1 Protein containing
supplement v non-protein
containing supplement
2 223 Risk Ratio (M-H, Fixed, 99% CI) 0.78 [0.65, 0.95]
Comparison 5. Thiamin (vitamin B1) and water soluble vitamins versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality by end of study 1 Risk Ratio (M-H, Fixed, 99% CI) Totals not selected
2 Patients with complications at
end of study
1 Risk Ratio (M-H, Fixed, 99% CI) Totals not selected
Comparison 6. Vitamin D versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients with complications at
end of study
1 Risk Ratio (M-H, Fixed, 99% CI) Totals not selected
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Comparison 7. Dietetic assistants versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality by end of study 1 Risk Ratio (M-H, Fixed, 99% CI) Totals not selected
2 Patients with complications at
end of study
1 Risk Ratio (M-H, Fixed, 99% CI) Totals not selected
Analysis 1.1. Comparison 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control,
Outcome 1 Mortality by end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control
Outcome: 1 Mortality by end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Oral supplements
Botella-Carretero 2008 0/60 0/30 0.0 [ 0.0, 0.0 ]
Brown 1992 0/5 0/5 0.0 [ 0.0, 0.0 ]
Bruce 2003 2/50 2/59 1.18 [ 0.09, 14.78 ]
Delmi 1990 6/27 10/32 0.71 [ 0.23, 2.24 ]
Hankins 1996 2/17 4/14 0.41 [ 0.05, 3.13 ]
Madigan 1994 4/18 0/12 6.16 [ 0.15, 255.68 ]
Miller 2006 1/23 4/20 0.22 [ 0.01, 3.47 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Tidermark 2004 1/20 1/20 1.00 [ 0.03, 34.83 ]
Subtotal (95% CI) 244 226 0.76 [ 0.42, 1.37 ]
Total events: 16 (Intervention), 21 (Control)
Heterogeneity: Chi2 = 4.31, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Nasogastric tube feeding
Bastow 1983 7/64 9/58 0.70 [ 0.21, 2.37 ]
Hartgrink 1998 7/70 0/70 15.00 [ 0.36, 629.78 ]
Sullivan 1998 0/8 5/10 0.11 [ 0.00, 4.17 ]
Subtotal (95% CI) 142 138 0.99 [ 0.50, 1.97 ]
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 14 (Intervention), 14 (Control)
Heterogeneity: Chi2 = 6.44, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 0.04 (P = 0.97)
3 Nasogastric tube feeding and oral supplements
Sullivan 2004 4/27 6/30 0.74 [ 0.16, 3.37 ]
Subtotal (95% CI) 27 30 0.74 [ 0.23, 2.35 ]
Total events: 4 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
4 Intravenous feeding and oral supplements
Eneroth 2006 0/40 4/40 0.11 [ 0.00, 4.95 ]
Subtotal (95% CI) 40 40 0.11 [ 0.01, 2.00 ]
Total events: 0 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 453 434 0.77 [ 0.51, 1.15 ]
Total events: 34 (Intervention), 45 (Control)
Heterogeneity: Chi2 = 12.16, df = 10 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 1.2. Comparison 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control,
Outcome 2 Patients with complications at end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control
Outcome: 2 Patients with complications at end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Oral supplements
Botella-Carretero 2008 32/60 15/30 1.07 [ 0.61, 1.87 ]
Delmi 1990 4/25 10/27 0.43 [ 0.11, 1.66 ]
Hankins 1996 5/17 6/12 0.59 [ 0.17, 1.99 ]
Madigan 1994 6/18 4/12 1.00 [ 0.26, 3.89 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Tidermark 2004 3/20 5/20 0.60 [ 0.11, 3.27 ]
Subtotal (95% CI) 164 135 0.81 [ 0.58, 1.13 ]
Total events: 50 (Intervention), 40 (Control)
Heterogeneity: Chi2 = 3.88, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Nasogastric tube feeding
Sullivan 1998 7/8 8/10 1.09 [ 0.64, 1.86 ]
Subtotal (95% CI) 8 10 1.09 [ 0.73, 1.64 ]
Total events: 7 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
3 Nasogastric tube feeding and oral supplements
Sullivan 2004 18/27 18/30 1.11 [ 0.66, 1.87 ]
Subtotal (95% CI) 27 30 1.11 [ 0.75, 1.65 ]
Total events: 18 (Intervention), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
4 Intravenous feeding and oral supplements
Eneroth 2006 6/40 28/40 0.21 [ 0.08, 0.59 ]
Subtotal (95% CI) 40 40 0.21 [ 0.10, 0.46 ]
Total events: 6 (Intervention), 28 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.95 (P = 0.000079)
Total (95% CI) 239 215 0.71 [ 0.57, 0.89 ]
Total events: 81 (Intervention), 94 (Control)
Heterogeneity: Chi2 = 23.63, df = 7 (P = 0.001); I2 =70%
Test for overall effect: Z = 2.95 (P = 0.0031)
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Analysis 1.3. Comparison 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control,
Outcome 3 Patients with complications at end of study: random-effects model.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control
Outcome: 3 Patients with complications at end of study: random-effects model
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,99% CI M-H,Random,99% CI
1 Oral supplements
Botella-Carretero 2008 32/60 15/30 1.07 [ 0.61, 1.87 ]
Delmi 1990 4/25 10/27 0.43 [ 0.11, 1.66 ]
Hankins 1996 5/17 6/12 0.59 [ 0.17, 1.99 ]
Madigan 1994 6/18 4/12 1.00 [ 0.26, 3.89 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Tidermark 2004 3/20 5/20 0.60 [ 0.11, 3.27 ]
Subtotal (95% CI) 164 135 0.86 [ 0.62, 1.20 ]
Total events: 50 (Intervention), 40 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.88, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 Nasogastric tube feeding
Sullivan 1998 7/8 8/10 1.09 [ 0.64, 1.86 ]
Subtotal (95% CI) 8 10 1.09 [ 0.73, 1.64 ]
Total events: 7 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
3 Nasogastric tube feeding and oral supplements
Sullivan 2004 18/27 18/30 1.11 [ 0.66, 1.87 ]
Subtotal (95% CI) 27 30 1.11 [ 0.75, 1.65 ]
Total events: 18 (Intervention), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
4 Intravenous feeding and oral supplements
Eneroth 2006 6/40 28/40 0.21 [ 0.08, 0.59 ]
Subtotal (95% CI) 40 40 0.21 [ 0.10, 0.46 ]
Total events: 6 (Intervention), 28 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.95 (P = 0.000079)
Total (95% CI) 239 215 0.73 [ 0.47, 1.12 ]
Total events: 81 (Intervention), 94 (Control)
Heterogeneity: Tau2 = 0.24; Chi2 = 23.63, df = 7 (P = 0.001); I2 =70%
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 1.4. Comparison 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control,
Outcome 4 Unfavourable outcome (death or complications) at end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control
Outcome: 4 Unfavourable outcome (death or complications) at end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Oral supplements
Botella-Carretero 2008 32/60 15/30 1.07 [ 0.61, 1.87 ]
Delmi 1990 10/25 20/27 0.54 [ 0.27, 1.08 ]
Hankins 1996 4/17 6/12 0.47 [ 0.12, 1.81 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 126 103 0.76 [ 0.55, 1.04 ]
Total events: 46 (Intervention), 41 (Control)
Heterogeneity: Chi2 = 4.84, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.74 (P = 0.082)
2 Nasogastric tube feeding
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Nasogastric tube feeding and oral supplements
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Intravenous feeding and oral supplements
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 126 103 0.76 [ 0.55, 1.04 ]
Total events: 46 (Intervention), 41 (Control)
Heterogeneity: Chi2 = 4.84, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.74 (P = 0.082)
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Analysis 1.5. Comparison 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control,
Outcome 5 Unfavourable outcome (death or complications) at end of study: random-effects model.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control
Outcome: 5 Unfavourable outcome (death or complications) at end of study: random-effects model
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Random,99% CI M-H,Random,99% CI
1 Oral supplements
Botella-Carretero 2008 32/60 15/30 1.07 [ 0.61, 1.87 ]
Delmi 1990 10/25 20/27 0.54 [ 0.27, 1.08 ]
Hankins 1996 4/17 6/12 0.47 [ 0.12, 1.81 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 126 103 0.71 [ 0.41, 1.22 ]
Total events: 46 (Intervention), 41 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 4.84, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Nasogastric tube feeding
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Nasogastric tube feeding and oral supplements
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Intravenous feeding and oral supplements
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 126 103 0.71 [ 0.41, 1.22 ]
Total events: 46 (Intervention), 41 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 4.84, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.25 (P = 0.21)
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Analysis 1.6. Comparison 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control,
Outcome 6 Unfavourable outcome (death or complications) - oral supplements extra analyses.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 1 Multinutrient supplement (oral, nasogastric, intravenous) versus control
Outcome: 6 Unfavourable outcome (death or complications) - oral supplements extra analyses
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Oral supplements: worst case scenario
Botella-Carretero 2008 32/60 15/30 1.07 [ 0.61, 1.87 ]
Delmi 1990 12/27 20/32 0.71 [ 0.37, 1.37 ]
Hankins 1996 4/17 6/14 0.55 [ 0.14, 2.18 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 128 110 0.85 [ 0.62, 1.15 ]
Total events: 48 (Intervention), 41 (Control)
Heterogeneity: Chi2 = 2.24, df = 2 (P = 0.33); I2 =11%
Test for overall effect: Z = 1.06 (P = 0.29)
2 Oral supplements: Hankins 1996 acute hospital data
Hankins 1996 14/17 12/14 0.96 [ 0.64, 1.44 ]
Subtotal (95% CI) 17 14 0.96 [ 0.71, 1.31 ]
Total events: 14 (Intervention), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
3 Oral supplements: Hankins 1996 post discharge
Hankins 1996 8/17 6/14 1.10 [ 0.39, 3.09 ]
Subtotal (95% CI) 17 14 1.10 [ 0.50, 2.41 ]
Total events: 8 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
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Analysis 2.1. Comparison 2 Multinutrient supplements (oral, nasogastric routes, intravenous) versus
control (split by nutritional status), Outcome 1 Mortality by end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 2 Multinutrient supplements (oral, nasogastric routes, intravenous) versus control (split by nutritional status)
Outcome: 1 Mortality by end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Malnourished targeted
Bastow 1983 7/64 9/58 0.70 [ 0.28, 1.77 ]
Brown 1992 0/5 0/5 0.0 [ 0.0, 0.0 ]
Hankins 1996 2/17 4/14 0.41 [ 0.09, 1.93 ]
Miller 2006 1/23 4/20 0.22 [ 0.03, 1.79 ]
Subtotal (95% CI) 109 97 0.52 [ 0.25, 1.07 ]
Total events: 10 (Intervention), 17 (Control)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
2 Malnourished not targeted
Botella-Carretero 2008 0/60 0/30 0.0 [ 0.0, 0.0 ]
Bruce 2003 2/50 2/59 1.18 [ 0.17, 8.08 ]
Delmi 1990 6/27 10/32 0.71 [ 0.30, 1.70 ]
Eneroth 2006 0/40 4/40 0.11 [ 0.01, 2.00 ]
Hartgrink 1998 7/70 0/70 15.00 [ 0.87, 257.70 ]
Madigan 1994 4/18 0/12 6.16 [ 0.36, 104.90 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Sullivan 1998 0/8 5/10 0.11 [ 0.01, 1.75 ]
Sullivan 2004 4/27 6/30 0.74 [ 0.23, 2.35 ]
Tidermark 2004 1/20 1/20 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 344 337 0.92 [ 0.56, 1.53 ]
Total events: 24 (Intervention), 28 (Control)
Heterogeneity: Chi2 = 10.29, df = 7 (P = 0.17); I2 =32%
Test for overall effect: Z = 0.30 (P = 0.76)
Total (95% CI) 453 434 0.77 [ 0.51, 1.15 ]
Total events: 34 (Intervention), 45 (Control)
Heterogeneity: Chi2 = 12.16, df = 10 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 2.2. Comparison 2 Multinutrient supplements (oral, nasogastric routes, intravenous) versus
control (split by nutritional status), Outcome 2 Patients with complications at end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 2 Multinutrient supplements (oral, nasogastric routes, intravenous) versus control (split by nutritional status)
Outcome: 2 Patients with complications at end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Malnourished targeted
Hankins 1996 5/17 6/12 0.59 [ 0.17, 1.99 ]
Subtotal (95% CI) 17 12 0.59 [ 0.23, 1.49 ]
Total events: 5 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 Malnourished not targeted
Botella-Carretero 2008 32/60 15/30 1.07 [ 0.61, 1.87 ]
Delmi 1990 4/25 10/27 0.43 [ 0.11, 1.66 ]
Eneroth 2006 6/40 28/40 0.21 [ 0.08, 0.59 ]
Madigan 1994 6/18 4/12 1.00 [ 0.26, 3.89 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Sullivan 1998 7/8 8/10 1.09 [ 0.64, 1.86 ]
Sullivan 2004 18/27 18/30 1.11 [ 0.66, 1.87 ]
Tidermark 2004 3/20 5/20 0.60 [ 0.11, 3.27 ]
Subtotal (95% CI) 222 203 0.72 [ 0.57, 0.91 ]
Total events: 76 (Intervention), 88 (Control)
Heterogeneity: Chi2 = 22.94, df = 6 (P = 0.00082); I2 =74%
Test for overall effect: Z = 2.75 (P = 0.0059)
Total (95% CI) 239 215 0.71 [ 0.57, 0.89 ]
Total events: 81 (Intervention), 94 (Control)
Heterogeneity: Chi2 = 23.63, df = 7 (P = 0.001); I2 =70%
Test for overall effect: Z = 2.95 (P = 0.0031)
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Analysis 2.3. Comparison 2 Multinutrient supplements (oral, nasogastric routes, intravenous) versus control
(split by nutritional status), Outcome 3 Unfavourable outcome (death or complications) at end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 2 Multinutrient supplements (oral, nasogastric routes, intravenous) versus control (split by nutritional status)
Outcome: 3 Unfavourable outcome (death or complications) at end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Malnourished targeted
Hankins 1996 4/17 6/12 0.47 [ 0.12, 1.81 ]
Subtotal (95% CI) 17 12 0.47 [ 0.17, 1.31 ]
Total events: 4 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
2 Malnourished not targeted
Botella-Carretero 2008 32/60 15/30 1.07 [ 0.61, 1.87 ]
Delmi 1990 10/25 20/27 0.54 [ 0.27, 1.08 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 109 91 0.81 [ 0.58, 1.12 ]
Total events: 42 (Intervention), 35 (Control)
Heterogeneity: Chi2 = 3.84, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 1.27 (P = 0.21)
Total (95% CI) 126 103 0.76 [ 0.55, 1.04 ]
Total events: 46 (Intervention), 41 (Control)
Heterogeneity: Chi2 = 4.84, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.74 (P = 0.082)
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Analysis 3.1. Comparison 3 Multinutrient supplements (oral, nasogastric routes, intravenous) versus
control (by allocation concealment), Outcome 1 Mortality by end of study (concealed? = yes; unclear; no).
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 3 Multinutrient supplements (oral, nasogastric routes, intravenous) versus control (by allocation concealment)
Outcome: 1 Mortality by end of study (concealed? = yes; unclear; no)
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Allocation concealed
Botella-Carretero 2008 0/60 0/30 0.0 [ 0.0, 0.0 ]
Hankins 1996 2/17 4/14 0.41 [ 0.05, 3.13 ]
Miller 2006 1/23 4/20 0.22 [ 0.01, 3.47 ]
Sullivan 1998 0/8 5/10 0.11 [ 0.00, 4.17 ]
Sullivan 2004 4/27 6/30 0.74 [ 0.16, 3.37 ]
Subtotal (95% CI) 135 104 0.39 [ 0.18, 0.85 ]
Total events: 7 (Intervention), 19 (Control)
Heterogeneity: Chi2 = 2.29, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.36 (P = 0.018)
2 Unclear if allocation concealed
Delmi 1990 6/27 10/32 0.71 [ 0.23, 2.24 ]
Eneroth 2006 0/40 4/40 0.11 [ 0.00, 4.95 ]
Hartgrink 1998 7/70 0/70 15.00 [ 0.36, 629.78 ]
Madigan 1994 4/18 0/12 6.16 [ 0.15, 255.68 ]
Stableforth 1986 0/24 0/34 0.0 [ 0.0, 0.0 ]
Tidermark 2004 1/20 1/20 1.00 [ 0.03, 34.83 ]
Subtotal (95% CI) 199 208 1.22 [ 0.65, 2.28 ]
Total events: 18 (Intervention), 15 (Control)
Heterogeneity: Chi2 = 8.36, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 0.61 (P = 0.54)
3 Allocation not concealed (quasi-randomised)
Bastow 1983 7/64 9/58 0.70 [ 0.21, 2.37 ]
Brown 1992 0/5 0/5 0.0 [ 0.0, 0.0 ]
Bruce 2003 2/50 2/59 1.18 [ 0.09, 14.78 ]
Subtotal (95% CI) 119 122 0.78 [ 0.34, 1.79 ]
Total events: 9 (Intervention), 11 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total (95% CI) 453 434 0.77 [ 0.51, 1.15 ]
Total events: 34 (Intervention), 45 (Control)
Heterogeneity: Chi2 = 12.16, df = 10 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 4.1. Comparison 4 High protein containing supplements versus low protein or non-protein
containing supplements, Outcome 1 Mortality by end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 4 High protein containing supplements versus low protein or non-protein containing supplements
Outcome: 1 Mortality by end of study
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Protein containing supplement v non-protein containing supplement
Espaulella 2000 21/85 13/86 61.1 % 1.63 [ 0.72, 3.71 ]
Schrch 1998 4/41 3/41 14.2 % 1.33 [ 0.20, 8.77 ]
Tkatch 1992 3/33 4/29 20.1 % 0.66 [ 0.10, 4.21 ]
Subtotal (95% CI) 159 156 95.5 % 1.38 [ 0.82, 2.34 ]
Total events: 28 (Intervention), 20 (Control)
Heterogeneity: Chi2 = 1.34, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
2 High protein containing supplement v low protein containing supplement
Neumann 2004 2/22 1/24 4.5 % 2.18 [ 0.10, 46.61 ]
Subtotal (95% CI) 22 24 4.5 % 2.18 [ 0.21, 22.42 ]
Total events: 2 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 181 180 100.0 % 1.42 [ 0.85, 2.37 ]
Total events: 30 (Intervention), 21 (Control)
Heterogeneity: Chi2 = 1.47, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 4.2. Comparison 4 High protein containing supplements versus low protein or non-protein
containing supplements, Outcome 2 Unfavourable outcome (death or complications) at end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 4 High protein containing supplements versus low protein or non-protein containing supplements
Outcome: 2 Unfavourable outcome (death or complications) at end of study
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Protein containing supplement v non-protein containing supplement
Espaulella 2000 49/80 59/81 70.5 % 0.84 [ 0.63, 1.12 ]
Tkatch 1992 17/33 23/29 29.5 % 0.65 [ 0.39, 1.07 ]
Total (95% CI) 113 110 100.0 % 0.78 [ 0.65, 0.95 ]
Total events: 66 (Intervention), 82 (Control)
Heterogeneity: Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 2.51 (P = 0.012)
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Analysis 5.1. Comparison 5 Thiamin (vitamin B1) and water soluble vitamins versus control, Outcome 1
Mortality by end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 5 Thiamin (vitamin B1) and water soluble vitamins versus control
Outcome: 1 Mortality by end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Day 1988 6/28 5/32 1.37 [ 0.33, 5.62 ]
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Analysis 5.2. Comparison 5 Thiamin (vitamin B1) and water soluble vitamins versus control, Outcome 2
Patients with complications at end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 5 Thiamin (vitamin B1) and water soluble vitamins versus control
Outcome: 2 Patients with complications at end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Day 1988 15/28 13/32 1.32 [ 0.65, 2.69 ]
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Analysis 6.1. Comparison 6 Vitamin D versus control, Outcome 1 Patients with complications at end of
study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 6 Vitamin D versus control
Outcome: 1 Patients with complications at end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Hoikka 1980 6/19 2/18 2.84 [ 0.41, 19.48 ]
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Analysis 7.1. Comparison 7 Dietetic assistants versus usual care, Outcome 1 Mortality by end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 7 Dietetic assistants versus usual care
Outcome: 1 Mortality by end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Duncan 2006 19/145 36/157 0.57 [ 0.29, 1.11 ]
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Analysis 7.2. Comparison 7 Dietetic assistants versus usual care, Outcome 2 Patients with complications at
end of study.
Review: Nutritional supplementation for hip fracture aftercare in older people
Comparison: 7 Dietetic assistants versus usual care
Outcome: 2 Patients with complications at end of study
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Duncan 2006 79/130 84/125 0.90 [ 0.71, 1.15 ]
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours control
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (Ovid)
1. exp fractures/
2. fracture$.tw
3. exp decubitus ulcer/
4. decubitus ulcer$.tw
5. pressure sore$. Tw
6. orthop$.tw
7. or/1-6
8. exp food/
9. food$.tw
10. diet$.tw
11. exp diet/
12. exp diet therapy/
13. exp nutrition/
14. nutri$.tw
15. exp nutrition disorders/
16. exp nutritional support/
17. supplement$.tw
18. weigh$.tw
19. exp body weight/
20. exp dietary fats/
21. exp dietary proteins/
22. exp dietary carbohydrates/
23. or/8-22
24. exp calcium, dietary/
25. exp phosphorus, dietary/
26. exp magnesium/
27. magnesium.tw
28. exp potassium, dietary/
29. exp sodium, dietary/
30. chloride$.tw
31. exp sulfur/
32. sulphate$.tw
33. sulfate$.tw
34. exp iron, dietary/
35. exp fluoride/
36. fluoride$.tw
37. exp trace elements/
38. trace element$.tw
39. trace metal$.tw
40. micronutrient$.tw
41. zinc.tw
42. copper.tw
43. selen$.tw
44. manganese.tw
45. molybdenum.tw
46. chromium.tw
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47. cobalt.tw
48. iodi#e$.tw
49. or/24-48
50. exp vitamins/
51. vitamin$.tw
52. ascorb$.tw
53. thiamin$.tw
54. riboflavin$.tw
55. pyridox$.tw
56. niacin$.tw
57. fola$.tw
58. folic.tw
59. biotin.tw
60. cobalamin$.tw
61. retino$.tw
62. exp carotenoid/
63. caroten$.tw
64. tocopher$.tw
65. dihydrotachysterol.tw
66. calcitriol.tw
67. cholecalciferol.tw
68. alfacalcidol.tw
69. alphacalcidol.tw
70. or/50-69
71. or/23,49,70
72. and/7,71
73. Randomized Controlled Trial.pt.
74. Controlled Clinical Trial.pt.
75. Random Allocation/
76. Double Blind Method/
77. Single Blind Method/
78. exp Cross-Over Studies/
79. or/73-78
80. ((clinical or controlled or comparative or placebo or prospective or randomi#ed) adj3 (trial or study)).tw
81. (random$ adj7 (allocat$ or allot$ or assign$ or basis$ or divid$ or order$)).tw
82. ((singl$ or doubl$ or trebl$ or tripl$) adj7 (blind$ or mask$)).tw
83. ((cross?over$ or (cross adj1 over$)).tw
84. ((allocat$ or allot$ or assign$ or divid$) adj3 (condition$ or experiment$ or intervention$ or treatment$ or therap$ or control$ or
group$)).tw
85. or/80-84
86. or/79,85
87. and/72,86
EMBASE (Ovid)
1. exp fractures/
2. fracture$.tw
3. exp decubitus ulcer/
4. decubitus ulcer$.tw
5. pressure sore$. tw
6. orthop$.tw
7. or/1-6
8. exp food/
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9. food$.tw
10. diet$.tw
11. exp diet/
12. exp diet therapy/
13. exp nutrition/
14. nutri$.tw
15. exp nutrition disorders/
16. exp nutritional support/
17. supplement$.tw
18. weigh$.tw
19. exp body weight/
20. exp dietary fats/
21. exp dietary proteins/
22. exp dietary carbohydrates/
23. or/8-22
24. exp calcium, dietary/
25. exp phosphorus, dietary/
26. exp magnesium/
27. magnesium.tw
28. exp potassium, dietary/
29. exp sodium, dietary/
30. chloride$.tw
31. exp sulfur/
32. sulphate$.tw
33. sulfate$.tw
34. exp iron, dietary/
35. exp fluoride/
36. fluoride$.tw
37. exp trace elements/
38. trace element$.tw
39. trace metal$.tw
40. micronutrient$.tw
41. zinc.tw
42. copper.tw
43. selen$.tw
44. manganese.tw
45. molybdenum.tw
46. chromium.tw
47. cobalt.tw
48. iodi#e$.tw
49. or/24-48
50. exp vitamins/
51. vitamin$.tw
52. ascorb$.tw
53. thiamin$.tw
54. riboflavin$.tw
55. pyridox$.tw
56. niacin$.tw
57. fola$.tw
58. folic.tw
59. biotin.tw
60. cobalamin$.tw
61. retino$.tw
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62. exp carotenoid/
63. caroten$.tw
64. tocopher$.tw
65. dihydrotachysterol.tw
66. calcitriol.tw
67. cholecalciferol.tw
68. alfacalcidol.tw
69. alphacalcidol.tw
70. or/50-69
71. or/23,49,70
72. and/7,71
73. clinical trial/
74. Multicenter Study/
75. phase 2 clinical trial/
76. phase 3 clinical trial/
77. phase 4 clinical trial/
78. Randomized Controlled Trial/
79. controlled study/
80. meta analysis/
81. crossover procedure/
82. double blind procedure/
83. single blind procedure/
84. randomization/
85. Major Clinical Study/
86. placebo/
87. drug comparison/
88. clinical study/
89. (clin$ adj25 trial$).tw
90. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw
91. placebo$.tw
92. random$.tw
93. control$.tw
94. or/73-93
95. and/72,94
Nutrition Abstracts and Reviews (Ovid)
1. exp fractures/
2. fracture$.tw
3. decubitus ulcer$.tw
4. pressure sore$.tw
5. orthop$.tw
6. or/1-5
7. dog$.tw
8. bird$.tw
9. horse$.tw
10. soil$.tw
11. wood$.tw
12. freeze fracture$.tw
13. or/7-12
14. random$.tw
15. trial$.tw
16. placebo$.tw
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17. or/14-16
18. and/6,17
19. 18 not 13
WH A T ’ S N E W
Last assessed as up-to-date: 28 February 2009.
12 November 2009 New citation required and conclusions have changed In this sixth update, published in Issue 1, 2010 of
The Cochrane Library, we updated our trial search to
September 2008. Of the 10 newly identified stud-
ies for this update, one trial is included (Botella-
Carretero 2008), five trials are excluded (Boudville
2002; Hommel 2007; Kacmaz 2007; Oloffson 2007;
Thomas 2008) and one trial awaits classification (
Gerstorfer 2008). Three new trials are ongoing (
Dagnelie; Houdijk; Miller). Of previously identified
trials: one former ongoing trial is now included (
Eneroth 2006), and one trial formerly awaiting classi-
fication (Miller 2006) is now included. A new category
(intravenous feeding and oral supplements)was set up
for one new trial.
There was slight modification to the conclusions that
reflected reappraisal of the available evidence.
H I S T O R Y
Protocol first published: Issue 1, 1999
Review first published: Issue 1, 2000
15 August 2008 Amended Converted to new review format.
4 August 2006 New search has been performed In the fifth update, published in The Cochrane Library Issue 4, 2006, we
updated our trial search to January 2006. Of the six newly identified studies
for this update, one trial is included (Sullivan 2004), three trials are excluded
(Ashworth 2006; Carlsson 2005; Wong 2004) and two trials await assess-
ment (Eneroth 2005; Stratton 2005). Of two former ongoing trials, one is
now included (Duncan 2006, formerly Johansen 2002) and the other awaits
assessment (Miller 2006, formerly Crotty 2003). One trial formerly await-
ing assessment is now included (Neumann 2004). Two existing categories
were modified to accommodate two newly included trials. A new category
(dietetic assistants versus usual care) was set up for the third new trial.
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(Continued)
3 November 2003 New search has been performed In the fourth update, published in The Cochrane Library Issue 1, 2004, we
updated our trial search to August 2003. Two new trials were included (Bruce
2003; Houwing 2003). Two newly identified trials were excluded (Hed-
ström 2002; Stumm 2001). One newly identified trial is awaiting assess-
ment (Tidermark 2003). Updates to all three ongoing trials were provided
(Cameron 2000; Crotty 2003; Johansen 2002). The review conclusions were
unchanged.
1 May 2002 New search has been performed In the third update, published in Issue 3, 2002 of The Cochrane Library,
we updated our trial search to April 2002. No new trials were included.
Two newly identified trials were excluded (Bachrach 2001; Lauque 2000).
Four trials previously awaiting assessment were now excluded. Two newly
identified trials (Crotty 2003; Johansen 2002) were included as ongoing
trials. The review conclusions were unchanged.
1 May 2001 New search has been performed In the second update, published in Issue 3, 2001 of The Cochrane Library,
the trial search was updated to April 2001. No new trials were included.
Two more trials were excluded: one previously awaiting assessment (Doshi
1998) on the basis of a full journal publication (Lawson 2000) and the
other (Bachrach 2000) was newly identified. One newly identified trial, only
available as a conference abstract, was placed in Studies awaiting assessment
(Moller-Madsen 1988) and further details sought. The review conclusions
were unchanged.
1 August 2000 New search has been performed In the first update, published in Issue 4, 2000 of The Cochrane Library, we
extended our trial search to January 2000. We identified one new ongoing
trial (Cameron 2000), and obtained new information on four included trials
and two studies placed in the awaiting assessment category in the first version
of this review. This extra information resulted in one included trial (Williams
1989) being excluded, and one of the two studies pending assessment being
included (Espaulella 2000) and the other excluded (Pedersen 1999).
The inclusion of the new trial, which evaluated the effect of protein in an
oral feed, and the other new information did not substantially alter the con-
clusions of the original review.
Relative risks instead of Peto odds ratios were presented for dichotomous
outcomes. Again, this did not affect the conclusions of the review.
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